Document:

<Page>

                                                                   Exhibit 10.78

                          SECURITIES PURCHASE AGREEMENT

     This Securities Purchase Agreement (this "AGREEMENT") is dated as of June
17, 2004, among Implant Sciences Corporation, a Massachusetts corporation (the
"COMPANY"), and each purchaser identified on the signature pages hereto (each,
including its successors and assigns, a "PURCHASER" and collectively the
"PURCHASERS"); and

     WHEREAS, subject to the terms and conditions set forth in this Agreement
and pursuant to Section 4(2) of the Securities Act (as defined below), and Rule
506 promulgated thereunder, the Company desires to issue and sell to each
Purchaser, and each Purchaser, severally and not jointly, desires to purchase
from the Company in the aggregate, $5,000,000 of shares of Common Stock,
Warrants and certain Additional Investment Rights on the Closing Date.

     NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this
Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agrees
as follows:

                                   ARTICLE I.
                                   DEFINITIONS

     1.1  DEFINITIONS. In addition to the terms defined elsewhere in this
Agreement, for all purposes of this Agreement, the following terms have the
meanings indicated in this Section 1.1:

          "ACTION" shall have the meaning ascribed to such term in Section
     3.1(j).

          "ADDITIONAL INVESTMENT RIGHT" means the Additional Investment Rights
     as described in Section 2.2(a)(iv).

          "ADDITIONAL INVESTMENT RIGHT SHARES" means the shares of Common Stock
     issuable upon exercise of the Additional Investment Rights.

          "AFFILIATE" means any Person that, directly or indirectly through one
     or more intermediaries, controls or is controlled by or is under common
     control with a Person as such terms are used in and construed under Rule
     144. With respect to a Purchaser, any investment fund or managed account
     that is managed on a discretionary basis by the same investment manager as
     such Purchaser will be deemed to be an Affiliate of such Purchaser.

          "CLOSING" means the closing of the purchase and sale of the Common
     Stock, the Warrants and the Additional Investment Rights pursuant to
     Section 2.1.

          "CLOSING DATE" means the Trading Day when all of the Transaction
     Documents have been executed and delivered by the applicable parties
     thereto, and all conditions precedent to (i) the Purchasers' obligations to
     pay the

                                        1
<Page>

     Subscription Amount and (ii) the Company's obligations to deliver the
     Securities have been satisfied or waived.

          "CLOSING PRICE" means on any particular date (a) the last reported
     closing price per share of Common Stock on such date on the Trading Market
     (as reported by Bloomberg L.P. at 4:15 PM (New York time) as the last
     reported closing price for regular session trading on such day), or (b) if
     there is no such price on such date, then the closing price on the Trading
     Market on the date nearest preceding such date (as reported by Bloomberg
     L.P. at 4:15 PM (New York time) as the closing price for regular session
     trading on such day), or (c) if the Common Stock is not then listed or
     quoted on the Trading Market and if prices for the Common Stock are then
     reported in the "pink sheets" published by the National Quotation Bureau
     Incorporated (or a similar organization or agency succeeding to its
     functions of reporting prices), the most recent bid price per share of the
     Common Stock so reported, or (d) if the shares of Common Stock are not then
     publicly traded the fair market value of a share of Common Stock as
     determined by an appraiser selected in good faith by the Purchasers of a
     majority in interest of the Shares then outstanding.

          "COMMISSION" means the Securities and Exchange Commission.

          "COMMON STOCK" means the common stock of the Company, par value $0.10
     per share, and any securities into which such common stock may hereafter be
     reclassified.

          "COMMON STOCK EQUIVALENTS" means any securities of the Company or the
     Subsidiaries which would entitle the holder thereof to acquire at any time
     Common Stock, including without limitation, any debt, preferred stock,
     rights, options, warrants or other instrument that is at any time
     convertible into or exchangeable for, or otherwise entitles the holder
     thereof to receive, Common Stock.

          "COMPANY COUNSEL" means Ellenoff Grossman & Schole LLP

          "DISCLOSURE SCHEDULES" means the Disclosure Schedules of the Company
     delivered concurrently herewith.

          "EFFECTIVE DATE" means the date that the Registration Statement is
     first declared effective by the Commission.

          "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended.

          "EXEMPT ISSUANCE" means the issuance of (a) shares of Common Stock or
     options to employees, consultants, officers or directors of the Company
     pursuant to any stock or option plan duly adopted by a majority of the
     non-employee members of the Board of Directors of the Company or a majority
     of the members of a committee of non-employee directors established for
     such purpose, (b) shares of Common Stock to employees approved by a
     majority of the non-employee

                                        2
<Page>

     members of the Board of Directors of the Company, (c) securities upon the
     exercise of or conversion of any securities issued hereunder, convertible
     securities, options or warrants issued and outstanding on the date of this
     Agreement, provided that such securities have not been amended since the
     date of this Agreement to increase the number of such securities, (d)
     securities issued in connection with the acquisition of assets, other than
     cash, licenses, sublicenses, intellectual property or proprietary
     rights,(e) securities issued pursuant to acquisitions or strategic
     transactions, provided any such issuance shall only be to a Person which
     is, itself or through its subsidiaries, an operating company in a business
     synergistic with the business of the Company and in which the Company
     receives benefits in addition to the investment of funds, but shall not
     include a transaction in which the Company is issuing securities primarily
     for the purpose of raising capital or to an entity whose primary business
     is investing in securities, and (f) shares of Common Stock upon exercise of
     warrants issued in connection with the initial public offering of the
     Company, including underwriters' warrants (as such warrants may be adjusted
     with respect to the extension of the exercise period thereof).

          "FW" means Feldman Weinstein LLP with offices located at 420
     Lexington Avenue, Suite 2620, New York, New York 10170-0002.

          "INTELLECTUAL PROPERTY RIGHTS" shall have the meaning ascribed to such
     term in Section 3.1(o).

          "LIENS" means a lien, charge, security interest, encumbrance, right of
     first refusal, preemptive right or other restriction.

          "MATERIAL ADVERSE EFFECT" shall have the meaning ascribed to such term
     in Section 3.1(b).

          "MATERIAL PERMITS" shall have the meaning ascribed to such term in
     Section 3.1(m).

          "PER SHARE PURCHASE PRICE" equals $10.67(1), subject to adjustment for
     reverse and forward stock splits, stock dividends, stock combinations and
     other similar transactions of the Common Stock that occur after the date of
     this Agreement.

          "PERSON" means an individual or corporation, partnership, trust,
     incorporated or unincorporated association, joint venture, limited
     liability company, joint stock company, government (or an agency or
     subdivision thereof) or other entity of any kind.

         "PROCEEDING" means an action, claim, suit, investigation or proceeding
     (including, without limitation, an investigation or partial proceeding,
     such as a

----------
(1)  85% of the lesser of (i) the average of the 5 consecutive Closing Prices
immediately prior to the date hereof and (ii) the Closing Price on the Trading
Day immediately prior to the date hereof.

                                        3
<Page>

     deposition), actually commenced or as to the threat of which the Company
     has actual knowledge.

          "REGISTRATION RIGHTS AGREEMENT" means the Registration Rights
     Agreement, dated as of the date of this Agreement, among the Company and
     each Purchaser, in the form of EXHIBIT A hereto.

          "REGISTRATION STATEMENT" means a registration statement meeting the
     requirements set forth in the Registration Rights Agreement and covering
     the resale by the Purchasers of the Shares, the Warrant Shares and the
     Additional Investment Right Shares.

          "REQUIRED APPROVALS" shall have the meaning ascribed to such term in
     Section 3.1(e).

          "RULE 144" means Rule 144 promulgated by the Commission pursuant to
     the Securities Act, as such Rule may be amended from time to time, or any
     similar rule or regulation hereafter adopted by the Commission having
     substantially the same effect as such Rule.

          "SEC REPORTS" shall have the meaning ascribed to such term in Section
     3.1(h).

          "SECURITIES" means the Shares, the Warrants, the Warrant Shares, the
     Additional Investment Rights and the Additional Investment Right Shares.

          "SECURITIES ACT" means the Securities Act of 1933, as amended.

          "SHARES" means the shares of Common Stock issued or issuable to each
     Purchaser pursuant to this Agreement.

          "SUBSCRIPTION AMOUNT" means, as to each Purchaser, the amounts set
     forth below such Purchaser's signature block on the signature page hereto,
     in United States dollars and in immediately available funds.

          "SUBSIDIARY" shall mean the subsidiaries of the Company, if any, set
     forth on SCHEDULE 3.1(a).

          "TRADING DAY" means a day on which the Common Stock is traded on a
     Trading Market.

          "TRADING MARKET" means the following markets or exchanges on which the
     Common Stock is listed or quoted for trading on the date in question: the
     Nasdaq SmallCap Market, the American Stock Exchange, the New York Stock
     Exchange, the Nasdaq National Market or the OTC Bulletin Board.

          "TRANSACTION DOCUMENTS" means this Agreement, the Warrants, the
     Additional Investment Rights and the Registration Rights Agreement and any

                                        4
<Page>

     other documents or agreements executed in connection with the transactions
     contemplated hereunder.

          "WARRANTS" means the Common Stock Purchase Warrants as described in
     Section 2.2(a)(iii).

          "WARRANT SHARES" means the shares of Common Stock issuable upon
     exercise of the Warrants.

                                   ARTICLE II.
                                PURCHASE AND SALE

     2.1  CLOSING. On the Closing Date, each Purchaser shall purchase from the
Company, severally and not jointly with the other Purchasers, and the Company
shall issue and sell to each Purchaser, (a) a number of Shares equal to such
Purchaser's Subscription Amount divided by the Per Share Purchase Price, (b) the
Warrants as determined pursuant to Section 2.2(a)(iii) and (c) the Additional
Investment Rights as determined pursuant to Section 2.2(a)(iv). The aggregate
Subscription Amounts for Shares sold hereunder shall be $5,000,000. Upon
satisfaction of the conditions set forth in Section 2.2, the Closing shall occur
at the offices of FW or such other location as the parties shall mutually agree.

     2.2  DELIVERIES.

          (a)  On the Closing Date,  the Company  shall  deliver or cause to be
     delivered to each Purchaser the following:

               (i)    this Agreement duly executed by the Company;

               (ii)   a copy of the irrevocable instructions to the Company's
          transfer agent instructing the transfer agent to deliver, on an
          expedited basis, a certificate evidencing a number of Shares equal to
          such Purchaser's Subscription Amount divided by the Per Share Purchase
          Price, registered in the name of such Purchaser;

               (iii)  a copy of a Warrant, registered in the name of such
          Purchaser, exercisable immediately upon issuance for a term of 5
          years, pursuant to which such Purchaser shall have the right to
          acquire up to the number of shares of Common Stock equal to 25% of the
          Shares to be issued to such Purchaser at an exercise price of
          $14.43(2), which Warrant shall otherwise in the form of EXHIBIT C
          attached hereto;

               (iv)   a copy of an Additional Investment Right, registered in
          the name of such Purchaser, pursuant to which such Purchaser shall
          have the right to purchase up to such Purchaser's pro rata share
          (based on the

----------
(2)  115% of the lesser of (i) the average of the 5 consecutive Closing Prices
immediately prior to the date hereof and (ii) the Closing Price immediately
prior to the date hereof.

                                        5
<Page>

          number of shares purchased hereunder) of $2,500,000 divided by the
          Additional Investment Right Exercise Price and which shall be
          exercisable immediately upon issuance until the earlier of (a) 100
          days after the Effective Date and (b) the 8 month anniversary of the
          Closing Date, at an exercise price equal to $11.61(3) (the "ADDITIONAL
          INVESTMENT RIGHT EXERCISE PRICE"), which Additional Investment Right
          shall otherwise in the form of EXHIBIT D attached hereto;

               (v)    the Registration Rights Agreement duly executed by the
          Company; and

               (vi)   a legal opinion of Company Counsel, in the form of
          EXHIBIT B attached hereto.

          (b)  On the Closing  Date,  each  Purchaser  shall deliver or cause to
     be delivered to the Company the following:

               (i)    this Agreement duly executed by such Purchaser;

               (ii)   such  Purchaser's  Subscription  Amount by wire  transfer
          to the account as specified in writing by the Company; and

               (iii)  the Registration Rights Agreement duly executed by such
          Purchaser.

     2.3  CLOSING CONDITIONS.

          (a)  The  obligations  of the  Company  hereunder  in  connection
     with the Closing are subject to the following conditions being met:

               (i)    the  accuracy  in all  material  respects  when  made  and
          on the Closing Date of the representations and warranties of the
          Purchasers contained herein;

               (ii)   all  obligations,  covenants and agreements of the
          Purchasers required to be performed at or prior to the Closing Date
          shall have been performed; and

               (iii)  the delivery by the Purchasers of the items set forth in
          Section 2.2(b) of this Agreement, including without limitation,
          Subscription Amounts in the aggregate of $5,000,000.

          (b)  The respective obligations of the Purchasers hereunder in
     connection with the Closing are subject to the following conditions being
     met:

----------
(3)  92.5% of the lesser of (i) the average of the 5 consecutive Closing Prices
immediately prior to the date hereof and (ii) the Closing Price immediately
prior to the date hereof.

                                        6
<Page>

               (i)    the accuracy in all material  respects on the Closing
          Date of the representations and warranties of the Company contained
          herein;

               (ii)   all  obligations,  covenants and  agreements of the
          Company required to be performed at or prior to the Closing Date shall
          have been performed;

               (iii)  the  delivery  by the  Company  of the  items  set  forth
          in Section 2.2(a) of this Agreement;

               (iv)   there shall have been no Material  Adverse  Effect with
          respect to the Company since the date hereof; and

               (v)    From the date hereof to the Closing Date, trading in the
          Common Stock shall not have been suspended by the Commission (except
          for any suspension of trading of limited duration agreed to by the
          Company, which suspension shall be terminated prior to the Closing),
          and, at any time prior to the Closing Date, trading in securities
          generally as reported by Bloomberg Financial Markets shall not have
          been suspended or limited, or minimum prices shall not have been
          established on securities whose trades are reported by such service,
          or on any Trading Market, nor shall a banking moratorium have been
          declared either by the United States or New York State authorities nor
          shall there have occurred any material outbreak or escalation of
          hostilities or other national or international calamity of such
          magnitude in its effect on, or any material adverse change in, any
          financial market which, in each case, in the reasonable judgment of
          each Purchaser, makes it impracticable or inadvisable to purchase the
          Shares at the Closing.

                                  ARTICLE III.
                         REPRESENTATIONS AND WARRANTIES

     3.1  REPRESENTATIONS AND WARRANTIES OF THE COMPANY. EXCEPT AS SET FORTH
UNDER THE CORRESPONDING SECTION OF THE DISCLOSURE SCHEDULES DELIVERED TO THE
PURCHASERS CONCURRENTLY HEREWITH (THE "DISCLOSURE SCHEDULES") WHICH DISCLOSURE
SCHEDULES SHALL BE DEEMED A PART HEREOF, THE COMPANY HEREBY MAKES THE
REPRESENTATIONS AND WARRANTIES SET FORTH BELOW TO EACH PURCHASERExcept as set
forth under the corresponding section of the Disclosure Schedules which
Disclosure Schedules shall be deemed a part hereof, the Company hereby makes the
representations and warranties set forth below to each Purchaser:

          (a)  SUBSIDIARIES. All of the direct and indirect subsidiaries of the
     Company are set forth on SCHEDULE 3.1(a). The Company owns, directly or
     indirectly, all of the capital stock or other equity interests of each
     Subsidiary free and clear of any Liens, and all the issued and outstanding
     shares of capital stock of each Subsidiary are validly issued and are fully
     paid, non-assessable and free of preemptive and similar rights to subscribe
     for or purchase securities. If the Company has no subsidiaries, then
     references in the Transaction Documents to the Subsidiaries will be
     disregarded.

          (b)  ORGANIZATION AND QUALIFICATION. Each of the Company and the
     Subsidiaries is an entity duly incorporated or otherwise organized, validly
     existing

                                        7
<Page>

     and in good standing under the laws of the jurisdiction of its
     incorporation or organization (as applicable), with the requisite authority
     to own and use its properties and assets and to carry on its business as
     currently conducted. Neither the Company nor any Subsidiary is in violation
     or default of any of the provisions of its respective certificate or
     articles of incorporation, bylaws or other organizational or charter
     documents. Each of the Company and the Subsidiaries is duly qualified to
     conduct business and is in good standing as a foreign corporation or other
     entity in each jurisdiction in which the nature of the business conducted
     or property owned by it makes such qualification necessary, except where
     the failure to be so qualified or in good standing, as the case may be,
     could not have or reasonably be expected to result in (i) a material
     adverse effect on the legality, validity or enforceability of any
     Transaction Document, (ii) a material adverse effect on the results of
     operations, assets, business, prospects or financial condition of the
     Company and the Subsidiaries, taken as a whole, or (iii) a material adverse
     effect on the Company's ability to perform in any material respect on a
     timely basis its obligations under any Transaction Document (any of (i),
     (ii) or (iii), a "MATERIAL ADVERSE EFFECT") and no Proceeding has been
     instituted in any such jurisdiction revoking, limiting or curtailing or
     seeking to revoke, limit or curtail such authority or qualification.

          (c)  AUTHORIZATION; ENFORCEMENT. The Company has the requisite
     corporate authority to enter into and to consummate the transactions
     contemplated by each of the Transaction Documents and otherwise to carry
     out its obligations thereunder. The execution and delivery of each of the
     Transaction Documents by the Company and the consummation by it of the
     transactions contemplated thereby have been duly authorized by all
     necessary action on the part of the Company and no further action is
     required by the Company in connection therewith other than in connection
     with the Required Approvals. Each Transaction Document has been (or upon
     delivery will have been) duly executed by the Company and, when delivered
     in accordance with the terms hereof, will constitute the valid and binding
     obligation of the Company enforceable against the Company in accordance
     with its terms except (i) as limited by applicable bankruptcy, insolvency,
     reorganization, moratorium and other laws of general application affecting
     enforcement of creditors' rights generally, (ii) as limited by laws
     relating to the availability of specific performance, injunctive relief or
     other equitable remedies and (iii) as limited by federal and state laws or
     the public policy underlying such laws with respect to indemnity or
     contribution.

          (d)  NO CONFLICTS. Except as set forth in SCHEDULE 3.1(d), the
     execution, delivery and performance of the Transaction Documents by the
     Company, the issuance and sale of the Shares and the consummation by the
     Company of the other transactions contemplated thereby do not and will not
     (i) conflict with or violate any provision of the Company's or any
     Subsidiary's certificate or articles of incorporation, bylaws or other
     organizational or charter documents, or (ii) conflict with, or constitute a
     default (or an event that with notice or lapse of time or both would become
     a default) under, result in the creation of any Lien upon any of the
     properties or assets of the Company or any

                                        8
<Page>

     Subsidiary, or give to others any rights of termination, amendment,
     acceleration or cancellation (with or without notice, lapse of time or
     both) of, any agreement, credit facility, debt or other instrument
     (evidencing a Company or Subsidiary debt or otherwise) or other
     understanding to which the Company or any Subsidiary is a party or by which
     any property or asset of the Company or any Subsidiary is bound or
     affected, or (iii) subject to the Required Approvals, conflict with or
     result in a violation of any law, rule, regulation, order, judgment,
     injunction, decree or other restriction of any court or governmental
     authority to which the Company or a Subsidiary is subject (including
     federal and state securities laws and regulations), or by which any
     property or asset of the Company or a Subsidiary is bound or affected, or
     (iv) conflict with or violate the terms of any agreement by which the
     Company or any Subsidiary is bound or to which any property or asset of the
     Company or any Subsidiary is bound or affected; except in the case of each
     of clauses (ii) and (iii), such as could not have or reasonably be expected
     to result in a Material Adverse Effect.

          (e)  FILINGS, CONSENTS AND APPROVALS. Except as set forth in SCHEDULE
     3.1(e), the Company is not required to obtain any consent, waiver,
     authorization or order of, give any notice to, or make any filing or
     registration with, any court or other federal, state, local or other
     governmental authority or other Person in connection with the execution,
     delivery and performance by the Company of the Transaction Documents, other
     than (i) filings required pursuant to Section 4.4 of this Agreement, (ii)
     the filing with the Commission of the Registration Statement, (iii)
     application(s) to each applicable Trading Market for the listing of the
     Shares, Warrant Shares and the Additional Investment Right Shares for
     trading thereon in the time and manner required thereby, and (iv) the
     filing of Form D with the Commission and such filings as are required to be
     made under applicable state securities laws (collectively, the "REQUIRED
     APPROVALS").

          (f)  ISSUANCE OF THE SECURITIES. The Shares, Warrants and Additional
     Investment Rights are duly authorized and, when issued and paid for in
     accordance with the Transaction Documents, will be duly and validly issued,
     fully paid and nonassessable, free and clear of all Liens imposed by the
     Company other than restrictions on transfer provided for in the Transaction
     Documents. The Warrant Shares and Additional Investment Right Shares, when
     issued in accordance with the terms of the Transaction Documents, will be
     validly issued, fully paid and nonassessable, free and clear of all Liens
     imposed by the Company. The Company has reserved from its duly authorized
     capital stock the maximum number of shares of Common Stock issuable
     pursuant to this Agreement, the Warrants and the Additional Investment
     Rights.

          (g)  CAPITALIZATION. The capitalization of the Company is as set forth
     on SCHEDULE 3.1(g). Except as set forth in SCHEDULE 3.1(g), the Company has
     not issued any capital stock since the filing of the Company's most recent
     periodic report other than pursuant to the exercise of employee stock
     options under the Company's stock option plans, the issuance of shares of
     Common Stock to employees pursuant to the Company's employee stock purchase
     plan and pursuant

                                        9
<Page>

     to the conversion or exercise of outstanding Common Stock Equivalents.
     Except as set forth in SCHEDULE 3.1(g), no Person has any right of first
     refusal, preemptive right, right of participation, or any similar right to
     participate in the transactions contemplated by the Transaction Documents.
     Except as a result of the purchase and sale of the Securities and as set
     forth in SCHEDULE 3.1(g), there are no outstanding options, warrants,
     script rights to subscribe to, calls or commitments of any character
     whatsoever relating to, or securities, rights or obligations convertible
     into or exchangeable for, or giving any Person any right to subscribe for
     or acquire, any shares of Common Stock, or contracts, commitments,
     understandings or arrangements by which the Company or any Subsidiary is or
     may become bound to issue additional shares of Common Stock, or securities
     or rights convertible or exchangeable into shares of Common Stock. Except
     as set forth in SCHEDULE 3.1(g), the issue and sale of the Securities will
     not obligate the Company to issue shares of Common Stock or other
     securities to any Person (other than the Purchasers) and will not result in
     a right of any holder of Company securities to adjust the exercise,
     conversion, exchange or reset price under such securities. All of the
     outstanding shares of capital stock of the Company are validly issued,
     fully paid and nonassessable, have been issued in compliance with all
     federal and state securities laws, and none of such outstanding shares was
     issued in violation of any preemptive rights or similar rights to subscribe
     for or purchase securities. No further approval or authorization of any
     stockholder, the Board of Directors of the Company or others is required
     for the issuance and sale of the Shares. Except as disclosed in the SEC
     Reports, there are no stockholders agreements, voting agreements or other
     similar agreements with respect to the Company's capital stock to which the
     Company is a party or, to the knowledge of the Company, between or among
     any of the Company's stockholders.

          (h)  SEC REPORTS; FINANCIAL STATEMENTS. The Company has filed all
     reports required to be filed by it under the Securities Act and the
     Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
     two years preceding the date hereof (or such shorter period as the Company
     was required by law to file such material) (the foregoing materials,
     including the exhibits thereto, being collectively referred to herein as
     the "SEC REPORTS") on a timely basis or has received a valid extension of
     such time of filing and has filed any such SEC Reports prior to the
     expiration of any such extension. As of their respective dates, the SEC
     Reports complied in all material respects with the requirements of the
     Securities Act and the Exchange Act and the rules and regulations of the
     Commission promulgated thereunder, and none of the SEC Reports, when filed,
     contained any untrue statement of a material fact or omitted to state a
     material fact required to be stated therein or necessary in order to make
     the statements therein, in light of the circumstances under which they were
     made, not misleading. The financial statements of the Company included in
     the SEC Reports comply in all material respects with applicable accounting
     requirements and the rules and regulations of the Commission with respect
     thereto as in effect at the time of filing. Such financial statements have
     been prepared in accordance with United States generally accepted
     accounting principles applied on a consistent basis during the periods
     involved ("GAAP"), except as may be otherwise specified in

                                       10
<Page>

     such financial statements or the notes thereto and except that unaudited
     financial statements may not contain all footnotes required by GAAP, and
     fairly present in all material respects the financial position of the
     Company and its consolidated subsidiaries as of and for the dates thereof
     and the results of operations and cash flows for the periods then ended,
     subject, in the case of unaudited statements, to normal, immaterial,
     year-end audit adjustments.

          (i)  MATERIAL CHANGES. Since the date of the latest audited financial
     statements included within the SEC Reports, except as specifically
     disclosed in the SEC Reports, (i) there has been no event, occurrence or
     development that has had or that could reasonably be expected to result in
     a Material Adverse Effect, (ii) the Company has not incurred any
     liabilities (contingent or otherwise) other than (A) trade payables and
     accrued expenses incurred in the ordinary course of business consistent
     with past practice and (B) liabilities not required to be reflected in the
     Company's financial statements pursuant to GAAP or required to be disclosed
     in filings made with the Commission, (iii) the Company has not altered its
     method of accounting, (iv) the Company has not declared or made any
     dividend or distribution of cash or other property to its stockholders or
     purchased, redeemed or made any agreements to purchase or redeem any shares
     of its capital stock and (v) the Company has not issued any equity
     securities to any officer, director or Affiliate, except pursuant to
     existing Company stock option plans. The Company does not have pending
     before the Commission any request for confidential treatment of
     information.

          (j)  LITIGATION. Except as set forth in SCHEDULE 3.1(j), there is no
     action, suit, inquiry, notice of violation, proceeding or investigation
     pending or, to the knowledge of the Company, threatened against or
     affecting the Company, any Subsidiary or any of their respective properties
     before or by any court, arbitrator, governmental or administrative agency
     or regulatory authority (federal, state, county, local or foreign)
     (collectively, an "ACTION") which (i) adversely affects or challenges the
     legality, validity or enforceability of any of the Transaction Documents or
     the Securities or (ii) could, if there were an unfavorable decision, have
     or reasonably be expected to result in a Material Adverse Effect. Neither
     the Company nor any Subsidiary, nor any director or officer thereof, is or
     has been the subject of any Action involving a claim of violation of or
     liability under federal or state securities laws or a claim of breach of
     fiduciary duty. There has not been, and to the knowledge of the Company,
     there is not pending or contemplated, any investigation by the Commission
     involving the Company or any current or former director or officer of the
     Company. The Commission has not issued any stop order or other order
     suspending the effectiveness of any registration statement filed by the
     Company or any Subsidiary under the Exchange Act or the Securities Act.

          (k)  LABOR RELATIONS. Except as set forth in SCHEDULE 3.1(k), no
     material labor dispute exists or, to the knowledge of the Company, is
     imminent with respect to any of the employees of the Company which could
     reasonably be expected to result in a Material Adverse Effect.

                                       11
<Page>

          (l)  COMPLIANCE. Neither the Company nor any Subsidiary (i) is in
     default under or in violation of (and no event has occurred that has not
     been waived that, with notice or lapse of time or both, would result in a
     default by the Company or any Subsidiary under), nor has the Company or any
     Subsidiary received notice of a claim that it is in default under or that
     it is in violation of, any indenture, loan or credit agreement or any other
     agreement or instrument to which it is a party or by which it or any of its
     properties is bound (whether or not such default or violation has been
     waived), (ii) is in violation of any order of any court, arbitrator or
     governmental body, or (iii) is or has been in violation of any statute,
     rule or regulation of any governmental authority, including without
     limitation all foreign, federal, state and local laws applicable to its
     business except in each case as could not have a Material Adverse Effect.

          (m)  REGULATORY PERMITS. The Company and the Subsidiaries possess all
     certificates, authorizations and permits issued by the appropriate federal,
     state, local or foreign regulatory authorities necessary to conduct their
     respective businesses as described in the SEC Reports, except where the
     failure to possess such permits could not have or reasonably be expected to
     result in a Material Adverse Effect ("MATERIAL PERMITS"), and neither the
     Company nor any Subsidiary has received any notice of proceedings relating
     to the revocation or modification of any Material Permit.

          (n)  TITLE TO ASSETS. The Company and the Subsidiaries have good and
     marketable title in fee simple to all real property owned by them that is
     material to the business of the Company and the Subsidiaries and good and
     marketable title in all personal property owned by them that is material to
     the business of the Company and the Subsidiaries, in each case free and
     clear of all Liens, except as set forth in SCHEDULE 3.1(n) and except for
     Liens as do not materially affect the value of such property and do not
     materially interfere with the use made and proposed to be made of such
     property by the Company and the Subsidiaries and Liens for the payment of
     federal, state or other taxes, the payment of which is neither delinquent
     nor subject to penalties. Any real property and facilities held under lease
     by the Company and the Subsidiaries are held by them under valid,
     subsisting and enforceable leases of which the Company and the Subsidiaries
     are in compliance.

          (o)  PATENTS AND TRADEMARKS. The Company and the Subsidiaries have, or
     have rights to use, all patents, patent applications, trademarks, trademark
     applications, service marks, trade names, copyrights, licenses and other
     similar rights necessary or material for use in connection with their
     respective businesses as described in the SEC Reports and which the failure
     to so have could have a Material Adverse Effect (collectively, the
     "INTELLECTUAL PROPERTY RIGHTS"). Neither the Company nor any Subsidiary has
     received a written notice that the Intellectual Property Rights used by the
     Company or any Subsidiary violates or infringes upon the rights of any
     Person. To the knowledge of the Company, all such Intellectual Property
     Rights are enforceable and there is no existing infringement by another
     Person of any of the Intellectual Property Rights of others.

                                       12
<Page>

          (p)  INSURANCE. The Company and the Subsidiaries are insured by
     insurers of recognized financial responsibility against such losses and
     risks and in such amounts as are prudent and customary in the businesses in
     which the Company and the Subsidiaries are engaged. To the best of
     Company's knowledge, such insurance contracts and policies are accurate and
     complete. Neither the Company nor any Subsidiary has any reason to believe
     that it will not be able to renew its existing insurance coverage as and
     when such coverage expires or to obtain similar coverage from similar
     insurers as may be necessary to continue its business without a significant
     increase in cost.

          (q)  TRANSACTIONS WITH AFFILIATES AND EMPLOYEES. Except as set forth
     in the SEC Reports, none of the officers or directors of the Company and,
     to the knowledge of the Company, none of the employees of the Company is
     presently a party to any transaction with the Company or any Subsidiary
     (other than for services as employees, officers and directors), including
     any contract, agreement or other arrangement providing for the furnishing
     of services to or by, providing for rental of real or personal property to
     or from, or otherwise requiring payments to or from any officer, director
     or such employee or, to the knowledge of the Company, any entity in which
     any officer, director, or any such employee has a substantial interest or
     is an officer, director, trustee or partner, in each case in excess of
     $60,000 other than (i) for payment of salary or consulting fees for
     services rendered, (ii) reimbursement for expenses incurred on behalf of
     the Company and (iii) for other employee benefits, including stock option
     agreements under any stock option plan of the Company.

          (r)  SARBANES-OXLEY; INTERNAL ACCOUNTING CONTROLS. Except as set forth
     in SCHEDULE 3.1(r), the Company is in material compliance with all
     provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as
     of the Closing Date. The Company and the Subsidiaries maintain a system of
     internal accounting controls sufficient to provide reasonable assurance
     that (i) transactions are executed in accordance with management's general
     or specific authorizations, (ii) transactions are recorded as necessary to
     permit preparation of financial statements in conformity with GAAP and to
     maintain asset accountability, (iii) access to assets is permitted only in
     accordance with management's general or specific authorization, and (iv)
     the recorded accountability for assets is compared with the existing assets
     at reasonable intervals and appropriate action is taken with respect to any
     differences. The Company has established disclosure controls and procedures
     (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
     and designed such disclosure controls and procedures to ensure that
     material information relating to the Company, including its subsidiaries,
     is made known to the certifying officers by others within those entities,
     particularly during the period in which the Company's most recently filed
     periodic report under the Exchange Act, as the case may be, is being
     prepared. The Company's certifying officers have evaluated the
     effectiveness of the Company's controls and procedures as of the date prior
     to the filing date of the most recently filed periodic report under the
     Exchange Act (such date, the "EVALUATION DATE"). The Company presented in
     its most recently filed periodic report under the Exchange Act the

                                       13
<Page>

     conclusions of the certifying officers about the effectiveness of the
     disclosure controls and procedures based on their evaluations as of the
     Evaluation Date. Since the Evaluation Date, there have been no significant
     changes in the Company's internal controls (as such term is defined in Item
     307(b) of Regulation S-K under the Exchange Act) or, to the Company's
     knowledge, in other factors that could significantly affect the Company's
     internal controls.

          (s)  CERTAIN FEES. No brokerage or finder's fees or commissions are or
     will be payable by the Company to any broker, financial advisor or
     consultant, finder, placement agent, investment banker, bank or other
     Person with respect to the transactions contemplated by this Agreement
     except for the payment of fees to Pacific Wave and the V Group. The
     Purchasers shall have no obligation with respect to any fees or with
     respect to any claims made by or on behalf of other Persons for fees of a
     type contemplated in this Section that may be due in connection with the
     transactions contemplated by this Agreement.

          (t)  PRIVATE PLACEMENT. Assuming the accuracy of the Purchasers
     representations and warranties set forth in Section 3.2, no registration
     under the Securities Act is required for the offer and sale of the
     Securities by the Company to the Purchasers as contemplated hereby. The
     issuance and sale of the Securities hereunder does not contravene the rules
     and regulations of the Trading Market.

          (u)  INVESTMENT COMPANY. The Company is not, and is not an Affiliate
     of, and immediately after receipt of payment for the Shares, will not be or
     be an Affiliate of, an "investment company" within the meaning of the
     Investment Company Act of 1940, as amended. The Company shall conduct its
     business in a manner so that it will not become subject to the Investment
     Company Act.

          (v)  REGISTRATION  RIGHTS.  Except as set forth in SCHEDULE  3.1(v),
     no Person has any right to cause the Company to effect the registration
     under the Securities Act of any securities of the Company.

          (w)  LISTING AND MAINTENANCE REQUIREMENTS. The Company's Common Stock
     is registered pursuant to Section 12(b) of the Exchange Act, and the
     Company has taken no action designed to, or which to its knowledge is
     likely to have the effect of, terminating the registration of the Common
     Stock under the Exchange Act nor has the Company received any notification
     that the Commission is contemplating terminating such registration. The
     Company has not, in the 12 months preceding the date hereof, received
     notice from any Trading Market on which the Common Stock is or has been
     listed or quoted to the effect that the Company is not in compliance with
     the listing or maintenance requirements of such Trading Market. The Company
     is, and has no reason to believe that it will not in the foreseeable future
     continue to be, in compliance with all such listing and maintenance
     requirements.

          (x)  APPLICATION OF TAKEOVER PROTECTIONS. The Company and its Board of
     Directors have taken all necessary action, if any, in order to render
     inapplicable

                                       14
<Page>

     any control share acquisition, business combination, poison pill (including
     any distribution under a rights agreement) or other similar anti-takeover
     provision under the Company's Certificate of Incorporation (or similar
     charter documents) or the laws of its state of incorporation that is or
     could become applicable to the Purchasers as a result of the Purchasers and
     the Company fulfilling their obligations or exercising their rights under
     the Transaction Documents, including without limitation the Company's
     issuance of the Securities and the Purchasers' ownership of the Securities.

          (y)  DISCLOSURE. The Company confirms that, neither the Company nor
     any other Person acting on its behalf has provided any of the Purchasers or
     their agents or counsel with any information that constitutes or might
     constitute material, non-public information other than information
     contained in the Disclosure Schedules. The Company understands and confirms
     that the Purchasers will rely on the foregoing representations and
     covenants in effecting transactions in securities of the Company. All
     disclosure provided to the Purchasers regarding the Company, its business
     and the transactions contemplated hereby, including the Disclosure
     Schedules to this Agreement, furnished by or on behalf of the Company with
     respect to the representations and warranties made herein are true and
     correct with respect to such representations and warranties and do not
     contain any untrue statement of a material fact or omit to state any
     material fact necessary in order to make the statements made therein, in
     light of the circumstances under which they were made, not misleading. The
     Company acknowledges and agrees that no Purchaser makes or has made any
     representations or warranties with respect to the transactions contemplated
     hereby other than those specifically set forth in Section 3.2 hereof.

          (z)  NO INTEGRATED OFFERING. Assuming the accuracy of the Purchasers'
     representations and warranties set forth in Section 3.2, neither the
     Company, nor any of its affiliates, nor any Person acting on its or their
     behalf has, directly or indirectly, made any offers or sales of any
     security or solicited any offers to buy any security, under circumstances
     that would cause this offering of the Securities to be integrated with
     prior offerings by the Company for purposes of the Securities Act or any
     applicable shareholder approval provisions, including, without limitation,
     under the rules and regulations of any exchange or automated quotation
     system on which any of the securities of the Company are listed or
     designated.

          (aa) SOLVENCY. Based on the financial condition of the Company as of
     the Closing Date after giving effect to the receipt by the Company of the
     proceeds from the sale of the Securities hereunder, (i) the Company's fair
     saleable value of its assets exceeds the amount that will be required to be
     paid on or in respect of the Company's existing debts and other liabilities
     (including known contingent liabilities) as they mature; and (ii) the
     current cash flow of the Company, together with the proceeds the Company
     would receive, were it to liquidate all of its assets, after taking into
     account all anticipated uses of the cash, would be sufficient to pay all
     amounts on or in respect of its debt when such amounts are required to be

                                       15
<Page>

     paid. The Company does not intend to incur debts beyond its ability to pay
     such debts as they mature (taking into account the timing and amounts of
     cash to be payable on or in respect of its debt).

          (bb) FORM S-3 ELIGIBILITY. The Company is eligible to register the
     resale of its Common Stock by the Purchasers under Form S-3 promulgated
     under the Securities Act and the Company hereby covenants and agrees to use
     its best efforts to maintain its eligibility to use Form S-3 until the
     Registration Statement covering the resale of the Shares shall have been
     filed with, and declared effective by, the Commission.

          (cc) TAXES. Except for matters that would not, individually or in the
     aggregate, have or reasonably be expected to result in a Material Adverse
     Effect, the Company and each Subsidiary has filed all necessary federal,
     state and foreign income and franchise tax returns and has paid or accrued
     all taxes shown as due thereon, and the Company has no knowledge of a tax
     deficiency which has been asserted or threatened against the Company or any
     Subsidiary.

          (dd) GENERAL SOLICITATION. Neither the Company nor any person acting
     on behalf of the Company has offered or sold any of the Shares by any form
     of general solicitation or general advertising. The Company has offered the
     Shares for sale only to the Purchasers and certain other "accredited
     investors" within the meaning of Rule 501 under the Securities Act.

          (ee) FOREIGN CORRUPT PRACTICES. Neither the Company, nor to the
     knowledge of the Company, any agent or other person acting on behalf of the
     Company, has (i) directly or indirectly, used any corrupt funds for
     unlawful contributions, gifts, entertainment or other unlawful expenses
     related to foreign or domestic political activity, (ii) made any unlawful
     payment to foreign or domestic government officials or employees or to any
     foreign or domestic political parties or campaigns from corporate funds,
     (iii) failed to disclose fully any contribution made by the Company (or
     made by any person acting on its behalf of which the Company is aware)
     which is in violation of law, or (iv) violated in any material respect any
     provision of the Foreign Corrupt Practices Act of 1977, as amended.

          (ff) ACCOUNTANTS. The Company's accountants are set forth on SCHEDULE
     3.1(FF) of the Disclosure Schedule. To the Company's knowledge, such
     accountants, who the Company expects will express their opinion with
     respect to the financial statements to be included in the Company's Annual
     Report on Form 10-KSB for the year ended June 30, 2003 are independent
     accountants as required by the Securities Act.

          (gg) ACKNOWLEDGMENT REGARDING PURCHASERS' PURCHASE OF SHARES. The
     Company acknowledges and agrees that each of the Purchasers is acting
     solely in the capacity of an arm's length purchaser with respect to the
     Transaction Documents and the transactions contemplated hereby. The Company
     further acknowledges that no Purchaser is acting as a financial advisor or
     fiduciary of the

                                       16
<Page>

     Company (or in any similar capacity) with respect to this Agreement and the
     transactions contemplated hereby and any advice given by any Purchaser or
     any of their respective representatives or agents in connection with this
     Agreement and the transactions contemplated hereby is merely incidental to
     the Purchasers' purchase of the Shares. The Company further represents to
     each Purchaser that the Company's decision to enter into this Agreement has
     been based solely on the independent evaluation of the transactions
     contemplated hereby by the Company and its representatives.

     3.2  REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS. Each Purchaser
hereby, for itself and for no other Purchaser, represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows:

          (a)  ORGANIZATION; AUTHORITY. Such Purchaser is an entity duly
     organized, validly existing and in good standing under the laws of the
     jurisdiction of its organization with full right, corporate or partnership
     authority to enter into and to consummate the transactions contemplated by
     the Transaction Documents and otherwise to carry out its obligations
     thereunder. The execution, delivery and performance by such Purchaser of
     the transactions contemplated by this Agreement have been duly authorized
     by all necessary corporate or similar action on the part of such Purchaser.
     Each Transaction Document to which it is a party has been duly executed by
     such Purchaser, and when delivered by such Purchaser in accordance with the
     terms hereof, will constitute the valid and legally binding obligation of
     such Purchaser, enforceable against it in accordance with its terms, except
     (i) as limited by general equitable principles and applicable bankruptcy,
     insolvency, reorganization, moratorium and other laws of general
     application affecting enforcement of creditors' rights generally, (ii) as
     limited by laws relating to the availability of specific performance,
     injunctive relief or other equitable remedies and (iii) insofar as
     indemnification and contribution provisions may be limited by applicable
     law.

          (b)  PURCHASER REPRESENTATION. Such Purchaser understands that the
     Securities are "restricted securities" and have not been registered under
     the Securities Act or any applicable state securities law and is acquiring
     the Securities as principal for its own account and not with a view to or
     for distributing or reselling such Securities or any part thereof, has no
     present intention of distributing any of such Securities and has no
     arrangement or understanding with any other persons regarding the
     distribution of such Securities (this representation and warranty not
     limiting such Purchaser's right to sell the Securities pursuant to the
     Registration Statement or otherwise in compliance with applicable federal
     and state securities laws). Such Purchaser is acquiring the Securities
     hereunder in the ordinary course of its business. Such Purchaser does not
     have any agreement or understanding, directly or indirectly, with any
     Person to distribute any of the Securities.

          (c)  PURCHASER STATUS. At the time such Purchaser was offered the
     Securities, it was, and at the date hereof it is, and on each date on which
     it

                                       17
<Page>

     exercises any Warrants or Additional Investment Rights, it will be either:
     (i) an "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3),
     (a)(7) or (a)(8) under the Securities Act or (ii) a "qualified
     institutional buyer" as defined in Rule 144A(a) under the Securities Act.
     Such Purchaser is not required to be registered as a broker-dealer under
     Section 15 of the Exchange Act.

          (d)  EXPERIENCE OF SUCH PURCHASER. Such Purchaser, either alone or
     together with its representatives, has such knowledge, sophistication and
     experience in business and financial matters so as to be capable of
     evaluating the merits and risks of the prospective investment in the
     Securities, and has so evaluated the merits and risks of such investment.
     Such Purchaser is able to bear the economic risk of an investment in the
     Securities and, at the present time, is able to afford a complete loss of
     such investment.

          (e)  GENERAL SOLICITATION. Such Purchaser is not purchasing the
     Securities as a result of any advertisement, article, notice or other
     communication regarding the Securities published in any newspaper, magazine
     or similar media or broadcast over television or radio or presented at any
     seminar or any other general solicitation or general advertisement.

          (f)  SHORT SALES. Each Purchaser represents that prior to execution of
     this Agreement, neither it nor any Person over which the Purchaser has
     direct control, have made any net short sales of, or granted any option for
     the purchase of or entered into any hedging or similar transaction with the
     same economic effect as a net short sale, in the Common Stock. Each
     Purchaser, severally and not jointly with the other Purchasers, understands
     and acknowledges that the SEC currently takes the position that coverage of
     short sales of shares of the Common Stock "against the box" with the
     Securities purchased hereunder prior to the Effective Date is a violation
     of Section 5 of the Securities Act, as set forth in Item 65, Section 5
     under Section A, of the Manual of Publicly Available Telephone
     Interpretations, dated July 1997, compiled by the Office of Chief Counsel,
     Division of Corporate Finance. Accordingly, each Purchaser hereby agrees
     not to use any of the Securities to cover any short sales prior to the
     Effective Date. Additionally, each Purchaser, severally and not jointly
     with the other Purchasers, agrees to comply with Regulation M under the
     federal securities laws.

     The Company acknowledges and agrees that each Purchaser does not make or
has not made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in this Section 3.2.

                                   ARTICLE IV.
                         OTHER AGREEMENTS OF THE PARTIES

     4.1  TRANSFER RESTRICTIONS.

          (a)  The Securities may only be disposed of in compliance with state
     and federal securities laws. In connection with any transfer of Securities
     other

                                       18
<Page>

     than pursuant to an effective registration statement or Rule 144, to the
     Company or to an Affiliate of a Purchaser or in connection with a pledge as
     contemplated in Section 4.1(b), the Company may require the transferor
     thereof to provide to the Company an opinion of counsel selected by the
     transferor and reasonably acceptable to the Company, the form and substance
     of which opinion and shall be reasonably satisfactory to the Company, to
     the effect that such transfer does not require registration of such
     transferred Securities under the Securities Act. As a condition of
     transfer, any such transferee shall agree in writing to be bound by the
     terms of this Agreement and shall have the rights of a Purchaser under this
     Agreement and the Registration Rights Agreement.

          (b)  The Purchasers agree to the imprinting, so long as is required by
     this Section 4.1(b), of a legend on any of the Securities in the following
     form:

          THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND
          EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
          RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
          OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT
          BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
          STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
          EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
          REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
          STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO
          THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE
          REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES MAY BE PLEDGED
          IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
          BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN
          "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES
          ACT.

          The Company acknowledges and agrees that a Purchaser may from time to
     time pledge pursuant to a bona fide margin agreement with a registered
     broker-dealer or grant a security interest in some or all of the Securities
     to a financial institution that is an "accredited investor" as defined in
     Rule 501(a) under the Securities Act and who agrees to be bound by the
     provisions of this Agreement and the Registration Rights Agreement and, if
     required under the terms of such arrangement, such Purchaser may transfer
     pledged or secured Securities to the pledgees or secured parties. Such a
     pledge or transfer would not be subject to approval of the Company and no
     legal opinion of legal counsel of the pledgee, secured party or pledgor
     shall be required in connection therewith. Further, no notice shall be
     required of such pledge. At the appropriate Purchaser's expense, the
     Company will execute and deliver such reasonable documentation as a

                                       19
<Page>

     pledgee or secured party of Securities may reasonably request in connection
     with a pledge or transfer of the Securities, including, if the Securities
     are subject to registration pursuant to the Registration Rights Agreement,
     the preparation and filing of any required prospectus supplement under Rule
     424(b)(3) under the Securities Act or other applicable provision of the
     Securities Act to appropriately amend the list of Selling Stockholders
     thereunder.

          (c)  Certificates evidencing the Shares, Warrant Shares and Additional
     Investment Right Shares shall not contain any legend (including the legend
     set forth in Section 4.1(b)), (i) while a registration statement (including
     the Registration Statement) covering the resale of such security is
     effective under the Securities Act, or (ii) following any sale of such
     Shares, Warrant Shares or Additional Investment Right Shares pursuant to
     Rule 144, or (iii) if such Shares, Warrant Shares or Additional Investment
     Right Shares are eligible for sale under Rule 144(k), or (iv) if such
     legend is not required under applicable requirements of the Securities Act
     (including judicial interpretations and pronouncements issued by the Staff
     of the Commission). The Company shall cause its counsel to issue a legal
     opinion to the Company's transfer agent promptly after the Effective Date
     if required by the Company's transfer agent to effect the removal of the
     legend hereunder. If all or any portion of a Warrant or Additional
     Investment Right is exercised at a time when there is an effective
     registration statement to cover the resale of the Warrant Shares or
     Additional Investment Right Shares, such Warrant Shares or Additional
     Investment Right Shares, as the case may be, shall be issued free of all
     legends. The Company agrees that following the Effective Date or at such
     time as such legend is no longer required under this Section 4.1(c) (unless
     the Company bona fide disputes any assertion by the Purchaser that such
     legend removal is proper under Section 4.1(c)(iv)), it will, no later than
     three Trading Days following the delivery by a Purchaser to the Company or
     the Company's transfer agent of a certificate representing Shares, Warrant
     Shares or Additional Investment Right Shares, as the case may be, issued
     with a restrictive legend (such date, the "LEGEND REMOVAL DATE"), deliver
     or cause to be delivered to such Purchaser a certificate representing such
     Securities that is free from all restrictive and other legends. The Company
     may not make any notation on its records or give instructions to any
     transfer agent of the Company that enlarge the restrictions on transfer set
     forth in this Section.

          (d)  In addition to such Purchaser's other available remedies, the
     Company shall pay to a Purchaser, in cash, as partial liquidated damages
     and not as a penalty, for each $1,000 of Shares, Warrant Shares or
     Additional Investment Right Shares (based on the Closing Price of the
     Common Stock on the date such Securities are submitted to the Company's
     transfer agent) subject to Section 4.1(c), $10 per Trading Day (increasing
     to $20 per Trading Day five (5) Trading Days after such damages have begun
     to accrue) for each Trading Day after the Legend Removal Date until such
     certificate is delivered. Nothing herein shall limit such Purchaser's right
     to pursue actual damages for the Company's failure to deliver certificates
     representing any Securities as required by the Transaction Documents, and
     such Purchaser shall have the right to pursue all remedies

                                       20
<Page>

     available to it at law or in equity including, without limitation, a decree
     of specific performance and/or injunctive relief.

          (e)  Each Purchaser, severally and not jointly with the other
     Purchasers, (i) agrees that the removal of the restrictive legend from
     certificates representing Securities as set forth in this Section 4.1 is
     predicated upon the Company's reliance that the Purchaser will sell any
     Securities pursuant to either the registration requirements of the
     Securities Act, including any applicable prospectus delivery requirements,
     or an exemption therefrom and (ii) undertakes to comply with applicable
     prospectus delivery requirements.

     4.2  FURNISHING OF INFORMATION. As long as any Purchaser owns Securities,
the Company covenants to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act. As long as any
Purchaser owns Securities, if the Company is not required to file reports
pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and
make publicly available in accordance with Rule 144(c) such information as is
required for the Purchasers to sell the Securities under Rule 144. The Company
further covenants that it will take such further action as any holder of
Securities may reasonably request, all to the extent required from time to time
to enable such Person to sell such Securities without registration under the
Securities Act within the limitation of the exemptions provided by Rule 144.

     4.3  INTEGRATION. The Company shall not sell, offer for sale or solicit
offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale
of the Securities in a manner that would require the registration under the
Securities Act of the sale of the Securities to the Purchasers or that would be
integrated with the offer or sale of the Securities for purposes of the rules
and regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder
approval is obtained before the closing of such subsequent transaction.

     4.4  SECURITIES LAWS DISCLOSURE; PUBLICITY. The Company shall, by 8:30 a.m.
Eastern time on the Trading Day following the date hereof, issue a press release
or file a Current Report on Form 8-K, in each case reasonably acceptable to each
Purchaser disclosing the material terms of the transactions contemplated hereby.
The Company and each Purchaser shall consult with each other in issuing any
other press releases with respect to the transactions contemplated hereby, and
neither the Company nor any Purchaser shall issue any such press release or
otherwise make any such public statement without the prior consent of the
Company, with respect to any press release of any Purchaser, or without the
prior consent of each Purchaser, with respect to any press release of the
Company, which consent shall not unreasonably be withheld, except if such
disclosure is required by law, in which case the disclosing party shall promptly
provide the other party with prior notice of such public statement or
communication. Notwithstanding the foregoing, the Company shall not publicly
disclose the name of any Purchaser, or include the name of any Purchaser in any
filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of such

                                       21
<Page>

Purchaser, except (i) as required by federal securities law in connection with
the registration statement contemplated by the Registration Rights Agreement and
(ii) to the extent such disclosure is required by law or Trading Market
regulations, in which case the Company shall provide the Purchasers with prior
notice of such disclosure permitted under subclause (i) or (ii).

     4.5  SHAREHOLDERS RIGHTS PLAN. No claim will be made or enforced by the
Company or, to the knowledge of the Company, any other Person that any Purchaser
is an "Acquiring Person" under any shareholders rights plan or similar plan or
arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by
virtue of receiving Securities under the Transaction Documents or under any
other agreement between the Company and the Purchasers. The Company shall
conduct its business in a manner so that it will not become subject to the
Investment Company Act.

     4.6  NON-PUBLIC INFORMATION. The Company covenants and agrees that neither
it nor any other Person acting on its behalf will provide any Purchaser or its
agents or counsel with any information that the Company believes constitutes
material non-public information, unless prior thereto such Purchaser shall have
executed a written agreement regarding the confidentiality and use of such
information. The Company understands and confirms that each Purchaser shall be
relying on the foregoing representations in effecting transactions in securities
of the Company.

     4.7  USE OF PROCEEDS. The Company shall use the net proceeds from the sale
of the Securities hereunder for the acquisition of businesses and assets and
working capital purposes and not for the satisfaction of any portion of the
Company's debt (other than payment of trade payables in the ordinary course of
the Company's business and prior practices), to redeem any Company equity or
equity-equivalent securities or to settle any outstanding litigation.

     4.8  REIMBURSEMENT. If any Purchaser becomes involved in any capacity in
any Proceeding by or against any Person who is a stockholder of the Company
(except as a result of sales, pledges, margin sales and similar transactions by
such Purchaser to or with any current stockholder, or unless such Proceeding is
based upon a breach of such Purchaser's representation, warranties or covenants
under the Transaction Documents or any agreements or understandings such
Purchaser may have with any such stockholder or any violations by such Purchaser
of state or federal securities laws or any conduct by such Purchaser which
constitutes fraud, or willful misconduct), solely as a result of such
Purchaser's acquisition of the Securities under this Agreement, the Company will
reimburse such Purchaser for its reasonable legal and other expenses (including
the cost of any investigation preparation and travel in connection therewith)
incurred in connection therewith, as such expenses are incurred. The
reimbursement obligations of the Company under this paragraph shall be in
addition to any liability which the Company may otherwise have, shall extend
upon the same terms and conditions to any Affiliates of the Purchasers who are
actually named in such action, proceeding or investigation, and partners,
directors, agents, employees and controlling persons (if any), as the case may
be, of the Purchasers and any such Affiliate, and shall be binding upon

                                       22
<Page>

and inure to the benefit of any successors, assigns, heirs and personal
representatives of the Company, the Purchasers and any such Affiliate and any
such Person. The Company also agrees that neither the Purchasers nor any such
Affiliates, partners, directors, agents, employees or controlling persons shall
have any liability to the Company or any Person asserting claims on behalf of or
in right of the Company solely as a result of acquiring the Securities under
this Agreement.

     4.9  INDEMNIFICATION OF PURCHASERS. Subject to the provisions of this
Section 4.9, the Company will indemnify and hold the Purchasers and their
directors, officers, shareholders, partners, employees and agents (each, a
"PURCHASER PARTY") harmless from any and all losses, liabilities, obligations,
claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys' fees and
costs of investigation that any such Purchaser Party may suffer or incur as a
result of or relating to (a) any breach of any of the representations,
warranties, covenants or agreements made by the Company in this Agreement or in
the other Transaction Documents or (b) any action instituted against a
Purchaser, or any of them or their respective Affiliates, by any stockholder of
the Company who is not an Affiliate of such Purchaser, with respect to any of
the transactions contemplated by the Transaction Documents (unless such action
is based upon a breach of such Purchaser's representation, warranties or
covenants under the Transaction Documents or any agreements or understandings
such Purchaser may have with any such stockholder or any violations by the
Purchaser of state or federal securities laws or any conduct by such Purchaser
which constitutes fraud, gross negligence, willful misconduct or malfeasance).
If any action shall be brought against any Purchaser Party in respect of which
indemnity may be sought pursuant to this Agreement, such Purchaser Party shall
promptly notify the Company in writing, and the Company shall have the right to
assume the defense thereof with counsel of its own choosing. Any Purchaser Party
shall have the right to employ separate counsel in any such action and
participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Purchaser Party except to the extent that (i)
the employment thereof has been specifically authorized by the Company in
writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the
reasonable opinion of such separate counsel, a material conflict on any material
issue between the position of the Company and the position of such Purchaser
Party. The Company will not be liable to any Purchaser Party under this
Agreement (i) for any settlement by an Purchaser Party effected without the
Company's prior written consent, which shall not be unreasonably withheld or
delayed; or (ii) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Party's breach of any of
the representations, warranties, covenants or agreements made by the Purchasers
in this Agreement or in the other Transaction Documents.

     4.10 RESERVATION OF COMMON STOCK. As of the date hereof, the Company has
reserved and the Company shall continue to reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock
for the purpose of enabling the Company to issue Shares pursuant to this
Agreement, Warrant Shares pursuant to any exercise of the Warrants and
Additional Investment Right Shares pursuant to any exercise of the Additional
Investment Rights.

                                       23
<Page>

     4.11 LISTING OF COMMON STOCK. The Company hereby agrees to use best efforts
to maintain the listing of the Common Stock on a Trading Market, and as soon as
reasonably practicable following the Closing (but not later than the earlier of
the Effective Date) to list all of the Shares, Warrant Shares and Additional
Investment Right Shares on such Trading Market. The Company further agrees, if
the Company applies to have the Common Stock traded on any other Trading Market,
it will include in such application all of the Shares, Warrant Shares and
Additional Investment Right Shares and will take such other action as is
necessary to cause all of the Shares, Warrant Shares and Additional Investment
Right Shares to be listed on such other Trading Market as promptly as possible.
The Company will take all action reasonably necessary to continue the listing
and trading of its Common Stock on a Trading Market and will comply in all
respects with the Company's reporting, filing and other obligations under the
bylaws or rules of the Trading Market.

     4.12 EQUAL TREATMENT OF PURCHASERS. No consideration shall be offered or
paid to any person to amend or consent to a waiver or modification of any
provision of any of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For
clarification purposes, this provision constitutes a separate right granted to
each Purchaser by the Company and negotiated separately by each Purchaser, and
is intended to treat for the Company the Purchasers as a class and shall not in
any way be construed as the Purchasers acting in concert or as a group with
respect to the purchase, disposition or voting of Securities or otherwise.

     4.13 PARTICIPATION IN FUTURE FINANCING. Subject to prior existing rights of
Laurus Funds, from the date hereof until 14 months after the Closing Date, upon
any financing by the Company of its Common Stock or Common Stock Equivalents (a
"SUBSEQUENT FINANCING"), each Purchaser shall have the right to participate in
up to 100% of such Subsequent Financing (the "PARTICIPATION MAXIMUM"); PROVIDED,
HOWEVER, if the lead investor in the Pre-Notice (as defined below) object to any
of the Purchaser's participation in the Subsequent Financing, the Purchasers'
rights hereunder, in the aggregate, shall be on an all or nothing basis. At
least 5 Trading Days prior to the closing of the Subsequent Financing, the
Company shall deliver to each Purchaser a written notice of its intention to
effect a Subsequent Financing ("PRE-NOTICE"), which Pre-Notice shall ask such
Purchaser if it wants to review the details of such financing (such additional
notice, a "SUBSEQUENT FINANCING NOTICE"). Upon the request of a Purchaser, and
only upon a request by such Purchaser, for a Subsequent Financing Notice, the
Company shall promptly, but no later than 1 Trading Day after such request,
deliver a Subsequent Financing Notice to such Purchaser. The Subsequent
Financing Notice shall describe in reasonable detail the proposed terms of such
Subsequent Financing, the amount of proceeds intended to be raised thereunder,
the Person with whom such Subsequent Financing is proposed to be effected, and
attached to which shall be a term sheet or similar document relating thereto. If
by 6:30 p.m. (New York City time) on the fifth Trading Day after all of the
Purchasers have received the Pre-Notice, notifications by the Purchasers of
their willingness to participate in the Subsequent Financing (or to cause their
designees to participate) is, in the aggregate, less than the total amount of
the Subsequent Financing, then the Company may effect the remaining portion of
such Subsequent Financing on the terms and to the Persons set forth in the
Subsequent

                                       24
<Page>

Financing Notice. If the Company receives no notice from a Purchaser as of such
5th Trading Day, such Purchaser shall be deemed to have notified the Company
that it does not elect to participate. The Company must provide the Purchasers
with a second Subsequent Financing Notice, and the Purchasers will again have
the right of participation set forth above in this Section 4.13, if the
Subsequent Financing subject to the initial Subsequent Financing Notice is not
consummated for any reason on the terms set forth in such Subsequent Financing
Notice within 60 Trading Days after the date of the initial Subsequent Financing
Notice. In the event the Company receives responses to Subsequent Financing
Notices from Purchasers seeking to purchase more than the aggregate amount of
the Subsequent Financing, each such Purchaser shall have the right to purchase
their Pro Rata Portion (as defined below) of the Participation Maximum. "PRO
RATA PORTION" is the ratio of (x) the Subscription Amount of Securities
purchased by a participating Purchaser and (y) the sum of the aggregate
Subscription Amount of all participating Purchasers. Notwithstanding the
foregoing, this Section 4.13 shall not apply in respect of an Exempt Issuance.

     4.14 SUBSEQUENT EQUITY SALES. From the date hereof until 30 days after the
Effective Date, neither the Company nor any Subsidiary shall issue shares of
Common Stock or Common Stock Equivalents; provided, however, the 30 day period
set forth in this Section 4.14 shall be extended for the number of Trading Days
during such period in which (y) trading in the Common Stock is suspended by any
Trading Market, or (z) following the Effective Date, the Registration Statement
is not effective or the prospectus included in the Registration Statement may
not be used by the Purchasers for the resale of the Shares, Warrant Shares and
Additional Investment Right Shares. Notwithstanding the foregoing, this Section
4.14 shall not apply in respect of an Exempt Issuance. In addition to the
limitations set forth herein, from the date hereof until 24 months from the
Closing Date, the Company shall be prohibited from effecting or enter into an
agreement to effect any Subsequent Financing involving a "VARIABLE RATE
TRANSACTION" or an "MFN TRANSACTION" (each as defined below). The term "VARIABLE
RATE TRANSACTION" shall mean a transaction (other than an Exempt Issuance) in
which the Company issues or sells (i) any debt or equity securities that are
convertible into, exchangeable or exercisable for, or include the right to
receive additional shares of Common Stock either (A) at a conversion, exercise
or exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for the shares of Common Stock at any time after
the initial issuance of such debt or equity securities, or (B) with a
conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock. The term "MFN
TRANSACTION" shall mean a transaction (other than an Exempt Issuance) in which
the Company issues or sells any securities in a capital raising transaction or
series of related transactions which grants to an investor the right to receive
additional shares based upon future transactions of the Company on terms more
favorable than those granted to such investor in such offering.

     4.15 DELIVERY OF SECURITIES AFTER CLOSING. The Company shall deliver, or
cause to be delivered, the respective Shares, Warrants and Additional Investment
Right

                                       25
<Page>

purchased by each Purchaser to such Purchaser within 3 Trading Days of the
Closing Date.

                                   ARTICLE V.
                                  MISCELLANEOUS

     5.1  FEES AND EXPENSES. The Company shall reimburse RAM Capital Resources
LLC ("RAM") up to the sum of $15,000 for its legal fees. The Company shall
deliver, prior to the Closing, a completed and executed copy of the Closing
Statement, attached hereto as ANNEX A. Except as otherwise set forth in this
Agreement, each party shall pay the fees and expenses of its advisers, counsel,
accountants and other experts, if any, and all other expenses incurred by such
party incident to the negotiation, preparation, execution, delivery and
performance of this Agreement. The Company shall pay all stamp and other taxes
and duties levied in connection with the sale of the Securities.

     5.2  ENTIRE AGREEMENT. The Transaction Documents, together with the
exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules.

     5.3  NOTICES. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be in writing and shall be
deemed given and effective on the earliest of (a) the date of transmission, if
such notice or communication is delivered via facsimile at the facsimile number
set forth on the signature pages attached hereto prior to 6:30 p.m. (New York
City time) on a Trading Day, (b) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number set forth on the signature pages attached hereto on a day that
is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading
Day, (c) the second Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service, or (d) upon actual receipt by
the party to whom such notice is required to be given. The address for such
notices and communications shall be as set forth on the signature pages attached
hereto.

     5.4  AMENDMENTS; WAIVERS. No provision of this Agreement may be waived or
amended except in a written instrument signed, in the case of an amendment, by
the Company and each Purchaser or, in the case of a waiver, by the party against
whom enforcement of any such waiver is sought. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be
deemed to be a continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or requirement hereof, nor
shall any delay or omission of either party to exercise any right hereunder in
any manner impair the exercise of any such right.

     5.5  CONSTRUCTION. The headings herein are for convenience only, do not
constitute a part of this Agreement and shall not be deemed to limit or affect
any of the

                                       26
<Page>

provisions hereof. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party.

     5.6  SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure
to the benefit of the parties and their successors and permitted assigns. The
Company may not assign this Agreement or any rights or obligations hereunder
without the prior written consent of each Purchaser. Any Purchaser may assign
any or all of its rights under this Agreement to any Person to whom such
Purchaser assigns or transfers any Securities, provided such transferee agrees
in writing to be bound, with respect to the transferred Securities, by the
provisions hereof that apply to the "Purchasers".

     5.7  NO THIRD-PARTY BENEFICIARIES. This Agreement is intended for the
benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person, except as otherwise set forth in Section 4.9.

     5.8  GOVERNING LAW. All questions concerning the construction, validity,
enforcement and interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of the State of
New York, without regard to the principles of conflicts of law thereof. Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect to
the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is improper or inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by
mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner
permitted by law. The parties hereby waive all rights to a trial by jury. If
either party shall commence an action or proceeding to enforce any provisions of
the Transaction Documents, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys' fees and
other costs and expenses incurred with the investigation, preparation and
prosecution of such action or proceeding.

     5.9  SURVIVAL. The representations and warranties herein shall survive the
Closing and delivery of the Shares, Warrant Shares and Additional Investment
Right Shares.

     5.10 EXECUTION. This Agreement may be executed in two or more counterparts,
all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and
delivered

                                       27
<Page>

to the other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile
transmission, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile signature page were an original thereof.

     5.11 SEVERABILITY. If any provision of this Agreement is held to be invalid
or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be
affected or impaired thereby and the parties will attempt to agree upon a valid
and enforceable provision that is a reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Agreement.

     5.12 RESCISSION AND WITHDRAWAL RIGHT. Notwithstanding anything to the
contrary contained in (and without limiting any similar provisions of) the
Transaction Documents, whenever any Purchaser exercises a right, election,
demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then such
Purchaser may rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights.

     5.13 REPLACEMENT OF SECURITIES. If any certificate or instrument evidencing
any Securities is mutilated, lost, stolen or destroyed, the Company shall issue
or cause to be issued in exchange and substitution for and upon cancellation
thereof, or in lieu of and substitution therefor, a new certificate or
instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction and customary and reasonable
indemnity, if requested. The applicants for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs
associated with the issuance of such replacement Securities.

     5.14 REMEDIES. In addition to being entitled to exercise all rights
provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the
Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of
obligations described in the foregoing sentence and hereby agrees to waive in
any action for specific performance of any such obligation the defense that a
remedy at law would be adequate.

     5.15 PAYMENT SET ASIDE. To the extent that the Company makes a payment or
payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the
proceeds of such enforcement or exercise or any part thereof are subsequently
invalidated, declared to be fraudulent or preferential, set aside, recovered
from, disgorged by or are required to be refunded, repaid or otherwise restored
to the Company, a trustee, receiver or any other person under any law
(including, without limitation, any bankruptcy law, state or federal law, common
law or equitable cause of action), then to the extent of any such restoration

                                       28
<Page>

the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been
made or such enforcement or setoff had not occurred.

     5.16 INDEPENDENT NATURE OF PURCHASERS' OBLIGATIONS AND RIGHTS. The
obligations of each Purchaser under any Transaction Document are several and not
joint with the obligations of any other Purchaser, and no Purchaser shall be
responsible in any way for the performance of the obligations of any other
Purchaser under any Transaction Document. Nothing contained herein or in any
Transaction Document, and no action taken by any Purchaser pursuant thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the
Purchasers are in any way acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Transaction Document. Each
Purchaser shall be entitled to independently protect and enforce its rights,
including without limitation, the rights arising out of this Agreement or out of
the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any proceeding for such
purpose. Each Purchaser has been represented by its own separate legal counsel
in their review and negotiation of the Transaction Documents. For reasons of
administrative convenience only, Purchasers and their respective counsel have
chosen to communicate with the Company through FW. FW does not represent all of
the Purchasers but only RAM, who has acted as placement agent to the
transaction. The Company has elected to provide all Purchasers with the same
terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by the Purchasers.

     5.17 LIQUIDATED DAMAGES. The Company's obligations to pay any partial
liquidated damages or other amounts owing under the Transaction Documents is a
continuing obligation of the Company and shall not terminate until all unpaid
partial liquidated damages and other amounts have been paid notwithstanding the
fact that the instrument or security pursuant to which such partial liquidated
damages or other amounts are due and payable shall have been canceled.

                            (SIGNATURE PAGE FOLLOWS)

                                       29
<Page>

          IN WITNESS WHEREOF, the parties hereto have caused this Securities
Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

IMPLANT SCIENCES CORPORATION                          ADDRESS FOR NOTICE:

By:
   ----------------------------------
   Name:
   Title:

With a copy to (which shall not constitute notice):

                   [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
                     SIGNATURE PAGES FOR PURCHASERS FOLLOW]

                                       30
<Page>

        [PURCHASER SIGNATURE PAGES TO IMX SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase
Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.

Name of Investing Entity: ______________________________________________________
SIGNATURE OF AUTHORIZED SIGNATORY OF INVESTING ENTITY: _________________________
Name of Authorized Signatory: __________________________________________________
Title of Authorized Signatory: _________________________________________________
Email Address of Authorized Entity:_____________________________________________

Address for Notice of Investing Entity:

Address for Delivery of Securities for Investing Entity (if not same as above):

Subscription Amount:
Shares:
Warrant Shares:
Additional Investment Right Shares:
EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

                           [SIGNATURE PAGES CONTINUE]

                                       31
<Page>

                                                                         ANNEX A

                                CLOSING STATEMENT

Pursuant to the attached Securities Purchase Agreement, dated as of the date
hereto, the purchasers shall purchase $5,000,000 of Common Stock, Warrants and
Additional Investment Right from Implant Sciences Corporation (the "COMPANY").
All funds will be wired to the Company. All funds will be disbursed in
accordance with this Closing Statement.

DISBURSEMENT DATE: June 17, 2004

I.   PURCHASE PRICE

<Table>
                   <S>                                           <C>
                   GROSS PROCEEDS TO BE RECEIVED IN TRUST        $ 5,000,004
</Table>

II.  DISBURSEMENTS

<Table>
                   <S>                                           <C>
                   Implant Sciences Corporation                  $ 4,710,004
                   Feldman Weinstein LLP                         $    15,000
                   Ellenoff Grossman Schole & Cyruli, LLP        $    25,000
                   Pacificwave Partners Limited                  $   200,000
                   U Group                                       $    50,000

TOTAL AMOUNT DISBURSED:                                          $ 5,000,004
</Table>

WIRE INSTRUCTIONS:

TO: IMPLANT SCIENCES CORPORATION
Citizens Providence
1 Citizens Bank
Riverside, RI 02915
ABA ROUTING NO: 011500120
ACCT NO: 113033-133-1
FOR FURTHER CREDIT TO: Implant Sciences Corporation
SWIFT CODE: CTZIUS33 (For international transfers)
PHONE #: 800-343-2258

TO: FELDMAN WEINSTEIN LLP
STERLING NATIONAL BANK
622 THIRD AVENUE
NEW YORK, NY 10017
ABA ROUTING NO: 026007773

                                       32
<Page>

ACCT NO: 08-141-85201
Acct Name: Feldman Weinstein LLP Operating Account "C"
Ref: RAM/IMX

TO: ELLENOFF GROSSMAN SCHOLE & CYRULI, LLP
The Citibank Private Bank
120 Broadway, 2nd Floor
New York, NY 10271
ABA Routing No.: 021000089
Account No.: 96613062
Contact: William Nastasi, 212-804-5512

TO: PACIFICWAVE PARTNERS LIMITED
Citibank
8900 Santa Monica Boulevard
Los Angeles, CA 90069
ABA Routing No.: 322271724
Account No.: 00200817765
Account Name: Bengal Capital Limited

TO: UGROUP

ABA Routing No.:
Account No.:
Contact:

                                       33<Page>

                                                                   Exhibit 10.79

                                                                       EXHIBIT C

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE
HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
REASONABLY ACCEPTABLE TO THE COMPANY TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR
OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS
DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT.

                          COMMON STOCK PURCHASE WARRANT

                To Purchase __________ Shares of Common Stock of

                          IMPLANT SCIENCES CORPORATION

          THIS COMMON STOCK PURCHASE WARRANT (the "WARRANT") CERTIFIES that, for
value received, _____________ (the "HOLDER"), is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set forth,
at any time on or after the date of issuance of this Warrant (the "INITIAL
EXERCISE DATE") and on or prior to the five year anniversary of the Initial
Exercise Date (the "TERMINATION DATE") but not thereafter, to subscribe for and
purchase from Implant Sciences Corporation, a Massachusetts corporation (the
"COMPANY"), up to ____________ shares (the "WARRANT SHARES") of Common Stock,
par value $0.10 per share, of the Company (the "COMMON STOCK"). The purchase
price of one share of Common Stock (the "EXERCISE PRICE") under this Warrant
shall be $14.43(1), subject to adjustment hereunder. The Exercise Price and the
number of Warrant Shares for which the Warrant is exercisable shall be subject
to adjustment as provided herein. CAPITALIZED TERMS USED AND NOT OTHERWISE
DEFINED HEREIN SHALL HAVE THE MEANINGS SET FORTH IN THAT CERTAIN SECURITIES
PURCHASE AGREEMENT (THE "PURCHASE AGREEMENT"), DATED JUNE 17, 2004 AMONG THE
COMPANY AND THE PURCHASERS SIGNATORY THERETO.

----------
(1)  115% of the lesser of (i) the average of the 5 consecutive Closing Prices
immediately prior to the date of the Purchase Agreement and (ii) the Closing
Price immediately prior to the date of the Purchase Agreement.

                                        1
<Page>

          1.   TITLE TO WARRANT. Prior to the Termination Date and subject to
compliance with applicable laws and Section 7 of this Warrant, this Warrant and
all rights hereunder are transferable, in whole or in part, at the office or
agency of the Company by the Holder in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed hereto
properly endorsed. The transferee shall sign an investment letter in form and
substance reasonably satisfactory to the Company.

          2.   AUTHORIZATION OF SHARES. The Company covenants that all Warrant
Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this
Warrant, be duly authorized, validly issued, fully paid and nonassessable and
free from all taxes, liens and charges in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such
issue).

          3.   EXERCISE OF WARRANT.

                      (a)  Exercise of the purchase rights represented by this
     Warrant may be made at any time or times on or after the Initial Exercise
     Date and on or before the Termination Date by delivery to the Company of a
     duly executed facsimile copy of the Notice of Exercise Form annexed hereto
     (or such other office or agency of the Company as it may designate by
     notice in writing to the registered Holder at the address of such Holder
     appearing on the books of the Company); provided, however, within 5 Trading
     Days of the date said Notice of Exercise is delivered to the Company, the
     Holder shall have surrendered this Warrant to the Company and the Company
     shall have received payment of the aggregate Exercise Price of the shares
     thereby purchased by wire transfer or cashier's check drawn on a United
     States bank. Certificates for shares purchased hereunder shall be
     transmitted by the transfer agent of the Company to the Holder by crediting
     the account of the Holder's prime broker with the Depository Trust Company
     through its Deposit Withdrawal Agent Commission ("DWAC") system within 3
     Trading Days from the delivery to the Company of the Notice of Exercise
     Form, surrender of this Warrant and payment of the aggregate Exercise Price
     as set forth above ("WARRANT SHARE DELIVERY DATE"). This Warrant shall be
     deemed to have been exercised on the date the Exercise Price is received by
     the Company. The Warrant Shares shall be deemed to have been issued, and
     Holder or any other person so designated to be named therein shall be
     deemed to have become a holder of record of such shares for all purposes,
     as of the date the Warrant has been exercised by payment to the Company of
     the Exercise Price and all taxes required to be paid by the Holder, if any,
     pursuant to Section 5 prior to the issuance of such shares, have been paid.
     If the Company fails to cause its transfer agent to transmit to the Holder
     through the DWAC system a certificate or certificates representing the
     Warrant Shares pursuant to this Section 3(a) by the Warrant Share Delivery
     Date, then the Holder will have the right to rescind such exercise. In
     addition to any other rights available to the Holder, if the Company fails
     to cause its transfer agent to transmit to the Holder through the DWAC
     system a certificate or certificates representing the Warrant Shares
     pursuant to an exercise by the Warrant Share Delivery Date, and if after
     such day the Holder is required by its broker to purchase (in an open
     market transaction

                                        2
<Page>

     or otherwise) shares of Common Stock to deliver in satisfaction of a sale
     by the Holder of the Warrant Shares which the Holder anticipated receiving
     upon such exercise (a "BUY-IN"), then the Company shall (1) pay in cash to
     the Holder the amount by which (x) the Holder's total purchase price
     (including brokerage commissions, if any) for the shares of Common Stock so
     purchased exceeds (y) the amount obtained by multiplying (A) the number of
     Warrant Shares that the Company was required to deliver to the Holder in
     connection with the exercise at issue times (B) the price at which the sell
     order giving rise to such purchase obligation was executed, and (2) at the
     option of the Holder, either reinstate the portion of the Warrant and
     equivalent number of Warrant Shares for which such exercise was not honored
     or deliver to the Holder the number of shares of Common Stock that would
     have been issued had the Company timely complied with its exercise and
     delivery obligations hereunder. For example, if the Holder purchases Common
     Stock having a total purchase price of $11,000 to cover a Buy-In with
     respect to an attempted exercise of shares of Common Stock with an
     aggregate sale price giving rise to such purchase obligation of $10,000,
     under clause (1) of the immediately preceding sentence the Company shall be
     required to pay the Holder $1,000. The Holder shall provide the Company
     written notice indicating the amounts payable to the Holder in respect of
     the Buy-In, together with applicable confirmations and other evidence
     reasonably requested by the Company. Nothing herein shall limit a Holder's
     right to pursue any other remedies available to it hereunder, at law or in
     equity including, without limitation, a decree of specific performance
     and/or injunctive relief with respect to the Company's failure to timely
     deliver certificates representing shares of Common Stock upon exercise of
     the Warrant as required pursuant to the terms hereof.

                      (b)  If this Warrant shall have been exercised in part,
     the Company shall, at the time of delivery of the certificate or
     certificates representing Warrant Shares, deliver to Holder a new Warrant
     evidencing the rights of Holder to purchase the unpurchased Warrant Shares
     called for by this Warrant, which new Warrant shall in all other respects
     be identical with this Warrant.

                      (c)  The Holder shall not have the right to exercise any
     portion of this Warrant, pursuant to Section 3(a) or otherwise, to the
     extent that after giving effect to such issuance after exercise, the Holder
     (together with the Holder's affiliates), as set forth on the applicable
     Notice of Exercise, would beneficially own in excess of 4.99% of the number
     of shares of the Common Stock outstanding immediately after giving effect
     to such issuance. For purposes of the foregoing sentence, the number of
     shares of Common Stock beneficially owned by the Holder and its affiliates
     shall include the number of shares of Common Stock issuable upon exercise
     of this Warrant with respect to which the determination of such sentence is
     being made, but shall exclude the number of shares of Common Stock which
     would be issuable upon (A) exercise of the remaining, nonexercised portion
     of this Warrant beneficially owned by the Holder or any of its affiliates
     and (B) exercise or conversion of the unexercised or nonconverted portion
     of any other securities of the Company (including, without limitation, any
     other Warrants) subject to a limitation on conversion or exercise analogous
     to the limitation contained herein beneficially owned by the Holder or any
     of its affiliates. Except as set forth in the preceding sentence, for
     purposes of this Section 3(c), beneficial ownership shall be calculated in
     accordance with Section 13(d) of the Exchange Act, it being acknowledged

                                        3
<Page>

     by Holder that the Company is not representing to Holder that such
     calculation is in compliance with Section 13(d) of the Exchange Act and
     Holder is solely responsible for any schedules required to be filed in
     accordance therewith. To the extent that the limitation contained in this
     Section 3(c) applies, the determination of whether this Warrant is
     exercisable (in relation to other securities owned by the Holder) and of
     which a portion of this Warrant is exercisable shall be in the sole
     discretion of such Holder, and the submission of a Notice of Exercise shall
     be deemed to be such Holder's determination of whether this Warrant is
     exercisable (in relation to other securities owned by such Holder) and of
     which portion of this Warrant is exercisable, in each case subject to such
     aggregate percentage limitation, and the Company shall have no obligation
     to verify or confirm the accuracy of such determination. For purposes of
     this Section 3(c), in determining the number of outstanding shares of
     Common Stock, the Holder may rely on the number of outstanding shares of
     Common Stock as reflected in (x) the Company's most recent Form 10-QSB or
     Form 10-KSB, as the case may be, (y) a more recent public announcement by
     the Company or (z) any other notice by the Company or the Company's
     Transfer Agent setting forth the number of shares of Common Stock
     outstanding. Upon the written or oral request of the Holder, the Company
     shall within two Trading Days confirm orally and in writing to the Holder
     the number of shares of Common Stock then outstanding. In any case, the
     number of outstanding shares of Common Stock shall be determined after
     giving effect to the conversion or exercise of securities of the Company,
     including this Warrant, by the Holder or its affiliates since the date as
     of which such number of outstanding shares of Common Stock was reported.

                      (d)  If at any time after one year from the date of
     issuance of this Warrant there is no effective Registration Statement
     registering the resale of the Warrant Shares by the Holder at such time
     (subject to any suspensions permitted pursuant to the Registration Rights
     Agreement), this Warrant may also be exercised at such time by means of a
     "cashless exercise" in which the Holder shall be entitled to receive a
     certificate for the number of Warrant Shares equal to the quotient obtained
     by dividing [(A-B) (X)] by (A), where:

          (A) = the Closing Price on the Trading Day immediately preceding the
                date of such election;

          (B) = the Exercise Price of this Warrant, as adjusted; and

          (X) = the number of Warrant Shares issuable upon exercise of this
                Warrant in accordance with the terms of this Warrant by means of
                a cash exercise rather than a cashless exercise.

          4.   NO FRACTIONAL SHARES OR SCRIP. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise be entitled
to purchase upon such exercise, the Company shall pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price.

                                        4
<Page>

          5.   CHARGES, TAXES AND EXPENSES. Issuance of certificates for Warrant
Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such certificate, all
of which taxes and expenses shall be paid by the Company, and such certificates
shall be issued in the name of the Holder or in such name or names as may be
directed by the Holder; PROVIDED, HOWEVER, that in the event certificates for
Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the
Assignment Form attached hereto duly executed by the Holder; and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto.

          6.   CLOSING OF BOOKS. The Company will not close its stockholder
books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

          7.   TRANSFER, DIVISION AND COMBINATION.

                      (a)  Subject to compliance with any applicable securities
     laws and the conditions set forth in Sections 1 and 7(e) hereof and to the
     provisions of Section 4.1 of the Purchase Agreement, this Warrant and all
     rights hereunder are transferable, in whole or in part, upon surrender of
     this Warrant at the principal office of the Company, together with a
     written assignment of this Warrant substantially in the form attached
     hereto duly executed by the Holder or its agent or attorney and funds
     sufficient to pay any transfer taxes payable upon the making of such
     transfer. Upon such surrender and, if required, such payment, the Company
     shall execute and deliver a new Warrant or Warrants in the name of the
     assignee or assignees and in the denomination or denominations specified in
     such instrument of assignment, and shall issue to the assignor a new
     Warrant evidencing the portion of this Warrant not so assigned, and this
     Warrant shall promptly be cancelled. A Warrant, if properly assigned, may
     be exercised by a new holder for the purchase of Warrant Shares without
     having a new Warrant issued.

                      (b)  This Warrant may be divided or combined with other
     Warrants upon presentation hereof at the aforesaid office of the Company,
     together with a written notice specifying the names and denominations in
     which new Warrants are to be issued, signed by the Holder or its agent or
     attorney. Subject to compliance with Section 7(a), as to any transfer which
     may be involved in such division or combination, the Company shall execute
     and deliver a new Warrant or Warrants in exchange for the Warrant or
     Warrants to be divided or combined in accordance with such notice.

                      (c)  The Company shall prepare, issue and deliver at its
     own expense (other than transfer taxes) the new Warrant or Warrants under
     this Section 7.

                      (d)  The Company agrees to maintain, at its aforesaid
     office, books for the registration and the registration of transfer of the
     Warrants.

                      (e)  If, at the time of the surrender of this Warrant in
     connection with any transfer of this Warrant, the transfer of this Warrant
     shall not be registered pursuant to an effective registration statement
     under the Securities Act and under applicable state

                                        5
<Page>

     securities or blue sky laws, the Company may require, as a condition of
     allowing such transfer (i) that the Holder or transferee of this Warrant,
     as the case may be, furnish to the Company a written opinion of counsel
     (which opinion shall be in form, substance and scope customary for opinions
     of counsel in comparable transactions) to the effect that such transfer may
     be made without registration under the Securities Act and under applicable
     state securities or blue sky laws, (ii) that the holder or transferee
     execute and deliver to the Company an investment letter in form and
     substance acceptable to the Company and (iii) that the transferee be an
     "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7),
     or (a)(8) promulgated under the Securities Act or a qualified institutional
     buyer as defined in Rule 144A(a) under the Securities Act.

          8.   NO RIGHTS AS SHAREHOLDER UNTIL EXERCISE. This Warrant does not
entitle the Holder to any voting rights or other rights as a shareholder of the
Company prior to the exercise hereof. Upon the surrender of this Warrant and the
payment of the aggregate Exercise Price (or by means of a cashless exercise),
the Warrant Shares so purchased shall be and be deemed to be issued to such
Holder as the record owner of such shares as of the close of business on the
later of the date of such surrender or payment.

          9.   LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. The Company
covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock
certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon
surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.

          10.  SATURDAYS, SUNDAYS, HOLIDAYS, ETC. If the last or appointed day
for the taking of any action or the expiration of any right required or granted
herein shall be a Saturday, Sunday or a legal holiday, then such action may be
taken or such right may be exercised on the next succeeding day not a Saturday,
Sunday or legal holiday.

          11.  ADJUSTMENTS OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.

          (a)  STOCK SPLITS, ETC. The number and kind of securities purchasable
     upon the exercise of this Warrant and the Exercise Price shall be subject
     to adjustment from time to time upon the happening of any of the following.
     In case the Company shall (i) pay a dividend in shares of Common Stock or
     make a distribution in shares of Common Stock to holders of its outstanding
     Common Stock, (ii) subdivide its outstanding shares of Common Stock into a
     greater number of shares, (iii) combine its outstanding shares of Common
     Stock into a smaller number of shares of Common Stock, or (iv) issue any
     shares of its capital stock in a reclassification of the Common Stock, then
     the number of Warrant Shares purchasable upon exercise of this Warrant
     immediately prior thereto shall be adjusted so that the Holder shall be
     entitled to receive the kind and number of Warrant Shares or other
     securities of the Company

                                        6
<Page>

     which it would have owned or have been entitled to receive had such Warrant
     been exercised in advance thereof. Upon each such adjustment of the kind
     and number of Warrant Shares or other securities of the Company which are
     purchasable hereunder, the Holder shall thereafter be entitled to purchase
     the number of Warrant Shares or other securities resulting from such
     adjustment at an Exercise Price per Warrant Share or other security
     obtained by multiplying the Exercise Price in effect immediately prior to
     such adjustment by the number of Warrant Shares purchasable pursuant hereto
     immediately prior to such adjustment and dividing by the number of Warrant
     Shares or other securities of the Company that are purchasable pursuant
     hereto immediately after such adjustment. An adjustment made pursuant to
     this paragraph shall become effective immediately after the effective date
     of such event retroactive to the record date, if any, for such event.

          (b)  ANTI-DILUTION PROVISIONS. During the Exercise Period, the
     Exercise Price shall be subject to adjustment from time to time as provided
     in this Section 11(b). In the event that any adjustment of the Exercise
     Price as required herein results in a fraction of a cent, such Exercise
     Price shall be rounded up or down to the nearest cent.

               (i)    ADJUSTMENT OF EXERCISE PRICE. If and whenever the Company
          issues or sells, or in accordance with Section 11(b)(ii) hereof is
          deemed to have issued or sold, any shares of Common Stock for an
          effective consideration per share of less than the then Exercise Price
          or for no consideration (such lower price, the "BASE SHARE PRICE" and
          such issuances collectively, a "DILUTIVE ISSUANCE"), then, (a) from
          the Initial Exercise Date until the 1 year anniversary of the
          Effective Date (if the Registration Statement is unavailable for use
          by the Holder during such period, such period shall be extended for
          such number of unavailable days), the Exercise Price shall be reduced
          to a price equal to 115% of the Base Share Price and (b) after the 1
          year anniversary of the Effective Date (as extended in clause (a)
          above), the Exercise Price shall be reduced by multiplying the
          Exercise Price by a fraction, the numerator of which is the number of
          shares of Common Stock issued and outstanding immediately prior to the
          Dilutive Issuance plus the number of shares of Common Stock which the
          offering price for such Dilutive Issuance would purchase at the then
          Exercise Price, and the denominator of which shall be the sum of the
          number of shares of Common Stock issued and outstanding immediately
          prior to the Dilutive Issuance plus the number of shares of Common
          Stock so issued or issuable in connection with the Dilutive Issuance.
          Such adjustment shall be made whenever shares of Common Stock or
          Common Stock Equivalents are issued.

               (ii)   EFFECT ON EXERCISE PRICE OF CERTAIN EVENTS. For purposes
          of determining the adjusted Exercise Price under Section 11(b) hereof,
          the following will be applicable:

                           (A)  ISSUANCE OF RIGHTS OR OPTIONS. If the Company in
               any manner issues or grants any warrants, rights or options,
               whether or not immediately exercisable, to subscribe for or to
               purchase Common Stock or Common Stock Equivalents (such warrants,
               rights and options to purchase Common Stock or Common Stock
               Equivalents are hereinafter referred to as "OPTIONS") and the
               effective price per share for which Common Stock is issuable upon
               the exercise of such Options is less than the Exercise

                                        7
<Page>

               Price ("BELOW BASE PRICE OPTIONS"), then the maximum total number
               of shares of Common Stock issuable upon the exercise of all such
               Below Base Price Options (assuming full exercise, conversion or
               exchange of Common Stock Equivalents, if applicable) will, as of
               the date of the issuance or grant of such Below Base Price
               Options, be deemed to be outstanding and to have been issued and
               sold by the Company for such price per share and the maximum
               consideration payable to the Company upon such exercise (assuming
               full exercise, conversion or exchange of Common Stock
               Equivalents, if applicable) will be deemed to have been received
               by the Company. For purposes of the preceding sentence, the
               "effective price per share for which Common Stock is issuable
               upon the exercise of such Below Base Price Options" is determined
               by dividing (i) the total amount, if any, received or receivable
               by the Company as consideration for the issuance or granting of
               all such Below Base Price Options, plus the minimum aggregate
               amount of additional consideration, if any, payable to the
               Company upon the exercise of all such Below Base Price Options,
               plus, in the case of Common Stock Equivalents issuable upon the
               exercise of such Below Base Price Options, the minimum aggregate
               amount of additional consideration payable upon the exercise,
               conversion or exchange thereof at the time such Common Stock
               Equivalents first become exercisable, convertible or
               exchangeable, by (ii) the maximum total number of shares of
               Common Stock issuable upon the exercise of all such Below Base
               Price Options (assuming full conversion of Common Stock
               Equivalents, if applicable). No further adjustment to the
               Exercise Price will be made upon the actual issuance of such
               Common Stock upon the exercise of such Below Base Price Options
               or upon the exercise, conversion or exchange of Common Stock
               Equivalents issuable upon exercise of such Below Base Price
               Options.

                           (B)  ISSUANCE OF COMMON STOCK EQUIVALENTS. If the
               Company in any manner issues or sells any Common Stock
               Equivalents, whether or not immediately convertible (other than
               where the same are issuable upon the exercise of Options) and the
               effective price per share for which Common Stock is issuable upon
               such exercise, conversion or exchange is less than the Exercise
               Price, then the maximum total number of shares of Common Stock
               issuable upon the exercise, conversion or exchange of all such
               Common Stock Equivalents will, as of the date of the issuance of
               such Common Stock Equivalents, be deemed to be outstanding and to
               have been issued and sold by the Company for such price per share
               and the maximum consideration payable to the Company upon such
               exercise (assuming full exercise, conversion or exchange of
               Common Stock Equivalents, if applicable) will be deemed to have
               been received by the Company. For the purposes of the preceding
               sentence, the "effective price per share for which Common Stock
               is issuable upon such exercise, conversion or exchange" is
               determined by dividing (i) the total amount, if any, received or
               receivable by the Company as consideration for the

                                        8
<Page>

               issuance or sale of all such Common Stock Equivalents, plus the
               minimum aggregate amount of additional consideration, if any,
               payable to the Company upon the exercise, conversion or exchange
               thereof at the time such Common Stock Equivalents first become
               exercisable, convertible or exchangeable, by (ii) the maximum
               total number of shares of Common Stock issuable upon the
               exercise, conversion or exchange of all such Common Stock
               Equivalents. No further adjustment to the Exercise Price will be
               made upon the actual issuance of such Common Stock upon exercise,
               conversion or exchange of such Common Stock Equivalents.

                           (C)  CHANGE IN OPTION PRICE OR CONVERSION RATE. If
               there is a change at any time in (i) the amount of additional
               consideration payable to the Company upon the exercise of any
               Options; (ii) the amount of additional consideration, if any,
               payable to the Company upon the exercise, conversion or exchange
               of any Common Stock Equivalents; or (iii) the rate at which any
               Common Stock Equivalents are convertible into or exchangeable for
               Common Stock (in each such case, other than under or by reason of
               provisions designed to protect against dilution), the Exercise
               Price in effect at the time of such change will be readjusted to
               the Exercise Price which would have been in effect at such time
               had such Options or Common Stock Equivalents still outstanding
               provided for such changed additional consideration or changed
               conversion rate, as the case may be, at the time initially
               granted, issued or sold.

                           (D)  CALCULATION OF CONSIDERATION RECEIVED. If any
               Common Stock, Options or Common Stock Equivalents are issued,
               granted or sold for cash, the consideration received therefor for
               purposes of this Warrant will be the amount received by the
               Company therefor, before deduction of reasonable commissions,
               underwriting discounts or allowances or other reasonable expenses
               paid or incurred by the Company in connection with such issuance,
               grant or sale. In case any Common Stock, Options or Common Stock
               Equivalents are issued or sold for a consideration part or all of
               which shall be other than cash, the amount of the consideration
               other than cash received by the Company will be the fair market
               value of such consideration, except where such consideration
               consists of securities, in which case the amount of consideration
               received by the Company will be the fair market value (closing
               price, if traded on any market) thereof as of the date of
               receipt. In case any Common Stock, Options or Common Stock
               Equivalents are issued in connection with any merger or
               consolidation in which the Company is the surviving corporation,
               the amount of consideration therefor will be deemed to be the
               fair market value of such portion of the net assets and business
               of the non-surviving corporation as is attributable to such
               Common Stock, Options or Common Stock Equivalents, as the case
               may be. The fair market value of any consideration other than
               cash or securities will be determined in good faith by an
               investment banker or other appropriate expert of national

                                        9
<Page>

               reputation selected by the Company and reasonably acceptable to
               the holder hereof, with the costs of such appraisal to be borne
               by the Company.

                           (E)  EXCEPTIONS TO ADJUSTMENT OF EXERCISE PRICE.
               Notwithstanding the foregoing, no adjustment will be made under
               this Section 11(b) in respect of an Exempt Issuance.

                           (F)  READJUSTMENT OF EXERCISE PRICE. In the event
               that the Exercise Price shall have been reduced pursuant to the
               provisions of this Section 11(b) but no Common Stock of the
               Company was actually or could in the future be issued in a
               Dilutive Issuance, then the Exercise Price shall be increased by
               the same amount that it was initially reduced.

               (iii)  OFFERINGS OF OTHER PROPERTY TO COMMON STOCK HOLDERS. If
          the Company, at any time prior to the Termination Date, shall
          distribute to all holders of Common Stock (and not to Holders of the
          Warrants) evidences of its indebtedness or assets or rights or
          warrants to subscribe for or purchase any security other than the
          Common Stock (which shall be subject to Section 11(a)(i)), then in
          each such case the Exercise Price shall be adjusted by multiplying the
          Exercise Price in effect immediately prior to the record date fixed
          for determination of stockholders entitled to receive such
          distribution by a fraction of which the denominator shall be the
          Closing Price determined as of the record date mentioned above, and of
          which the numerator shall be such Closing Price on such record date
          less the then per share fair market value at such record date of the
          portion of such assets or evidence of indebtedness so distributed
          applicable to one outstanding share of the Common Stock as determined
          by the Board of Directors in good faith. In either case the
          adjustments shall be described in a statement provided to the Holders
          of the portion of assets or evidences of indebtedness so distributed
          or such subscription rights applicable to one share of Common Stock.
          Such adjustment shall be made whenever any such distribution is made
          and shall become effective immediately after the record date mentioned
          above.

               (iv)   MINIMUM ADJUSTMENT OF EXERCISE PRICE. No adjustment of the
          Exercise Price shall be made in an amount of less than 1% of the
          Exercise Price in effect at the time such adjustment is otherwise
          required to be made, but any such lesser adjustment shall be carried
          forward and shall be made at the time and together with the next
          subsequent adjustment which, together with any adjustments so carried
          forward, shall amount to not less than 1% of such Exercise Price.

          12.  REORGANIZATION, RECLASSIFICATION, MERGER, CONSOLIDATION OR
DISPOSITION OF ASSETS. In case the Company shall reorganize its capital,
reclassify its capital stock, consolidate or merge with or into another
corporation (where the Company is not the surviving corporation or where there
is a change in or distribution with respect to the Common Stock of the Company),

                                       10
<Page>

or sell, transfer or otherwise dispose of its property, assets or business to
another corporation and, pursuant to the terms of such reorganization,
reclassification, merger, consolidation or disposition of assets, shares of
common stock of the successor or acquiring corporation, or any cash, shares of
stock or other securities or property of any nature whatsoever (including
warrants or other subscription or purchase rights) in addition to or in lieu of
common stock of the successor or acquiring corporation ("OTHER PROPERTY"), are
to be received by or distributed to the holders of Common Stock of the Company,
then the Holder shall have the right thereafter to receive, at the option of the
Holder, upon exercise of this Warrant, the number of shares of Common Stock of
the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and Other Property receivable upon or as a result of such
reorganization, reclassification, merger, consolidation or disposition of assets
by a Holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such event. In the case of any such
reorganization, reclassification, merger, consolidation or disposition of
assets, the successor or acquiring corporation (if other than the Company) shall
expressly assume the due and punctual observance and performance of each and
every covenant and condition of this Warrant to be performed and observed by the
Company and all the obligations and liabilities hereunder, subject to such
modifications as may be deemed appropriate (as determined in good faith by
resolution of the Board of Directors of the Company) in order to provide for
adjustments of Warrant Shares for which this Warrant is exercisable which shall
be as nearly equivalent as practicable to the adjustments provided for in this
Section 12. For purposes of this Section 12, "common stock of the successor or
acquiring corporation" shall include stock of such corporation of any class
which is not preferred as to dividends or assets over any other class of stock
of such corporation and which is not subject to redemption and shall also
include any evidences of indebtedness, shares of stock or other securities which
are convertible into or exchangeable for any such stock, either immediately or
upon the arrival of a specified date or the happening of a specified event and
any warrants or other rights to subscribe for or purchase any such stock. The
foregoing provisions of this Section 12 shall similarly apply to successive
reorganizations, reclassifications, mergers, consolidations or disposition of
assets.

          13.  VOLUNTARY ADJUSTMENT BY THE COMPANY. The Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any
amount and for any period of time deemed appropriate by the Board of Directors
of the Company.

          14.  NOTICE OF ADJUSTMENT. Whenever the number of Warrant Shares or
number or kind of securities or other property purchasable upon the exercise of
this Warrant or the Exercise Price is adjusted, as herein provided, the Company
shall give notice thereof to the Holder, which notice shall state the number of
Warrant Shares (and other securities or property) purchasable upon the exercise
of this Warrant and the Exercise Price of such Warrant Shares (and other
securities or property) after such adjustment, setting forth a brief statement
of the facts requiring such adjustment and setting forth the computation by
which such adjustment was made.

          15.  NOTICE OF CORPORATE ACTION. If at any time:

               (a)    the Company shall take a record of the holders of its
     Common Stock for the purpose of entitling them to receive a dividend or
     other distribution, or any right to subscribe for or purchase any evidences
     of its indebtedness, any shares of stock of any class or any other
     securities or property, or to receive any other right, or

                                       11
<Page>

               (b)    there shall be any capital reorganization of the Company,
     any reclassification or recapitalization of the capital stock of the
     Company or any consolidation or merger of the Company with, or any sale,
     transfer or other disposition of all or substantially all the property,
     assets or business of the Company to, another corporation or,

               (c)    there shall be a voluntary or involuntary dissolution,
     liquidation or winding up of the Company;

then, in any one or more of such cases, the Company shall use its best efforts
to give to Holder (i) at least 20 days' prior written notice of the date on
which a record date shall be selected for such dividend, distribution or right
or for determining rights to vote in respect of any such reorganization,
reclassification, merger, consolidation, sale, transfer, disposition,
liquidation or winding up, and (ii) in the case of any such reorganization,
reclassification, merger, consolidation, sale, transfer, disposition,
dissolution, liquidation or winding up, at least 20 days' prior written notice
of the date when the same shall take place. Such notice in accordance with the
foregoing clause also shall specify (i) the date on which any such record is to
be taken for the purpose of such dividend, distribution or right, the date on
which the holders of Common Stock shall be entitled to any such dividend,
distribution or right, and the amount and character thereof, and (ii) the date
on which any such reorganization, reclassification, merger, consolidation, sale,
transfer, disposition, dissolution, liquidation or winding up is to take place
and the time, if any such time is to be fixed, as of which the holders of Common
Stock shall be entitled to exchange their Warrant Shares for securities or other
property deliverable upon such disposition, dissolution, liquidation or winding
up. Each such written notice shall be sufficiently given if addressed to Holder
at the last address of Holder appearing on the books of the Company and
delivered in accordance with Section 17(d).

          16.  AUTHORIZED SHARES. The Company covenants that during the period
the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the
Warrant Shares upon the exercise of any purchase rights under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such
Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.

               Except and to the extent as waived or consented to by the Holder,
the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this
Warrant against impairment. Without limiting the generality of the foregoing,
the Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in
par value,

                                       12
<Page>

(b) take all such action as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Warrant
Shares upon the exercise of this Warrant, and (c) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof as may be necessary to enable
the Company to perform its obligations under this Warrant.

               Before taking any action which would result in an adjustment in
the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions
thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

          17.  MISCELLANEOUS.

                      (a)  JURISDICTION. All questions concerning the
     construction, validity, enforcement and interpretation of this Warrant
     shall be determined in accordance with the provisions of the Purchase
     Agreement.

                      (b)  RESTRICTIONS. The Holder acknowledges that the
     Warrant Shares acquired upon the exercise of this Warrant, if not
     registered, will have restrictions upon resale imposed by state and federal
     securities laws.

                      (c)  NONWAIVER AND EXPENSES. No course of dealing or any
     delay or failure to exercise any right hereunder on the part of Holder
     shall operate as a waiver of such right or otherwise prejudice Holder's
     rights, powers or remedies, notwithstanding all rights hereunder terminate
     on the Termination Date. If the Company willfully and knowingly fails to
     comply with any provision of this Warrant, which results in any material
     damages to the Holder, the Company shall pay to Holder such amounts as
     shall be sufficient to cover any costs and expenses including, but not
     limited to, reasonable attorneys' fees, including those of appellate
     proceedings, incurred by Holder in collecting any amounts due pursuant
     hereto or in otherwise enforcing any of its rights, powers or remedies
     hereunder.

                      (d)  NOTICES. Any notice, request or other document
     required or permitted to be given or delivered to the Holder by the Company
     shall be delivered in accordance with the notice provisions of the Purchase
     Agreement.

                      (e)  LIMITATION OF LIABILITY. No provision hereof, in the
     absence of any affirmative action by Holder to exercise this Warrant or
     purchase Warrant Shares, and no enumeration herein of the rights or
     privileges of Holder, shall give rise to any liability of Holder for the
     purchase price of any Common Stock or as a stockholder of the Company,
     whether such liability is asserted by the Company or by creditors of the
     Company.

                      (f)  REMEDIES. Holder, in addition to being entitled to
     exercise all rights granted by law, including recovery of damages, will be
     entitled to specific performance of its rights under this Warrant. The
     Company agrees that monetary damages would not be adequate compensation for
     any loss incurred by reason of a breach by it of the provisions of this
     Warrant and hereby agrees to waive the defense in any action for specific
     performance that a remedy at law would be adequate.

                                       13
<Page>

                      (g)  SUCCESSORS AND ASSIGNS. Subject to applicable
     securities laws, this Warrant and the rights and obligations evidenced
     hereby shall inure to the benefit of and be binding upon the successors of
     the Company and the successors and permitted assigns of Holder. The
     provisions of this Warrant are intended to be for the benefit of all
     Holders from time to time of this Warrant and shall be enforceable by any
     such Holder or holder of Warrant Shares.

                      (h)  AMENDMENT. This Warrant may be modified or amended or
     the provisions hereof waived with the written consent of the Company and
     the Holder.

                      (i)  SEVERABILITY. Wherever possible, each provision of
     this Warrant shall be interpreted in such manner as to be effective and
     valid under applicable law, but if any provision of this Warrant shall be
     prohibited by or invalid under applicable law, such provision shall be
     ineffective to the extent of such prohibition or invalidity, without
     invalidating the remainder of such provisions or the remaining provisions
     of this Warrant.

                      (j)  HEADINGS. The headings used in this Warrant are for
     the convenience of reference only and shall not, for any purpose, be deemed
     a part of this Warrant.

                              ********************

                                       14
<Page>

          IN WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its officer thereunto duly authorized.

Dated:  June _____, 2004

                                        IMPLANT SCIENCES CORPORATION

                                        By:
                                           -------------------------------------
                                           Name:
                                           Title:

                                       15
<Page>

                               NOTICE OF EXERCISE

To: Implant Sciences Corporation

          (1)  The undersigned hereby elects to purchase ________ Warrant Shares
of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together
with all applicable transfer taxes, if any.

          (2)  Payment shall take the form of (check applicable box):

                      [ ] in lawful money of the United States; or

                      [ ] the cancellation of such number of Warrant Shares as
                      is necessary, in accordance with the formula set forth in
                      subsection 3(d), to exercise this Warrant with respect to
                      the maximum number of Warrant Shares purchasable pursuant
                      to the cashless exercise procedure set forth in subsection
                      3(d).

          (3)  Please issue a certificate or certificates representing said
Warrant Shares in the name of the undersigned or in such other name as is
specified below:

                      _____________________________________

The Warrant Shares shall be delivered to the following:

                      _____________________________________

                      _____________________________________

                      _____________________________________

          (4)  ACCREDITED INVESTOR. The undersigned is an "accredited investor"
as defined in Regulation D under the Securities Act of 1933, as amended.

                                           [PURCHASER]

                                           By:
                                              -------------------------
                                           Name:
                                           Title:

                                           Dated:
                                                 ----------------------

<Page>

                                 ASSIGNMENT FORM

                    (To assign the foregoing warrant, execute
                   this form and supply required information.
                 Do not use this form to exercise the warrant.)

          FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to

_______________________________________________ whose address is

________________________________________________________________________.

________________________________________________________________________

                                                     Dated:
                                                           -------------, ------

                      Holder's Signature:
                                           ---------------------------

                      Holder's Address:
                                           ---------------------------

                                           ---------------------------

Signature Guaranteed:
                      ------------------------------------------------

NOTE: The signature to this Assignment Form must correspond with the name as it
appears on the face of the Warrant, without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank or trust company. Officers
of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]